<%BANNER%>
Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse mod...
CITATION PDF VIEWER
Full Citation
STANDARD VIEW MARC VIEW
Permanent Link: http://ufdc.ufl.edu/AA00010539/00001
 Material Information
Title: Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren’s syndrome
Series Title: Arthritis Research & Therapy
Physical Description: Archival
Language: English
Creator: Yin, Hongen
Nguyen, Cuong Q.
Samuni, Yuval
Uede, Toshimitsu
Peck, Ammon B.
Chiorini, John A.
Publisher: BioMed Central
Publication Date: 2012
 Subjects
Subjects / Keywords: Sjögren’s Syndrome
salivary gland dysfunction
adeno-associated virus (AAV)
CTLA4IgG fusion protein
prevention
 Notes
Abstract: Introduction: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key negative costimulatory molecule that displays a wide range of anti-inflammatory properties and is currently approved to treat rheumatoid arthritis as a recombinant fusion protein (CTLA4IgG). To better understand the role of CTLA4IgG in primary Sjögren’s syndrome (pSS), we generated a recombinant adeno-associated virus vector serotype 2 (AAV2) expressing a chimera of mouse CTLA-4 fused with a human immunoglobulin (AAV2-CTLA4IgG) and observed the effect of this molecule in C57BL/6.NOD-Aec1Aec2 mice, an animal model of pSS. Methods: A recombinant adeno-associated virus-2 (AAV-2) vector was constructed encoding a CTLA4IgG fusion protein. The AAV2-CTLA4IgG vector and an AAV2 control vector encoding beta galactosidase (LacZ) were administered by retrograde cannulation of the submandibular glands of C57BL/6.NOD-Aec1Aec2 mice. Protein expression was measured by ELISA and salivary glands were assessed for inflammation and activity. Results: Recombinant CTLA4IgG blocked B7 expression on macrophages in vitro. In vivo, localized expression of CTLA4IgG in the salivary glands of C57BL/6.NOD-Aec1Aec2 mice inhibited the loss of salivary gland activity and decreased T and B cell infiltration as well as dendritic cells and macrophages in the glands compared with control mice. In addition a decrease in several proinflammatory cytokines and an increase in transforming growth factor beta-1 (TGF-b1) expression were also observed. Conclusions: These data suggest expression of CTLA4IgG in the salivary gland can decrease the inflammation and improve the xerostomia reported in these mice. Keywords: Sjögren’s Syndrome, salivary gland dysfunction, adeno-associated virus (AAV), CTLA4IgG fusion protein, prevention
 Record Information
Source Institution: University of Florida
Holding Location: University of Florida
Rights Management:
This item is licensed with the Creative Commons Attribution License. This license lets others distribute, remix, tweak, and build upon this work, even commercially, as long as they credit the author for the original creation.
Resource Identifier: doi - 10.1186/ar3753
System ID: AA00010539:00001

Downloads

This item is only available as the following downloads:

( XML )

( PDF )

BioMed Central METS ( XML )


Full Text

PAGE 1

RESEARCHARTICLE OpenAccessLocaldeliveryofAAV2-CTLA4IgGdecreases sialadenitisandimprovesglandfunctioninthe C57BL/6.NODAec1Aec2 mousemodelofSjgren s syndromeHongenYin1,CuongQNguyen2,YuvalSamuni1,ToshimitsuUede3,AmmonBPeck2andJohnAChiorini1*AbstractIntroduction: CytotoxicT-lymphocyteantigen4(CTLA-4)isakeynegativecostimulatorymoleculethatdisplaysa widerangeofanti-inflammatorypropertiesandiscurrentlyapprovedtotreatrheumatoidarthritisasa recombinantfusionprotein(CTLA4IgG).TobetterunderstandtheroleofCTLA4IgGinprimarySjgren ssyndrome (pSS),wegeneratedarecombinantadeno-associatedvirusvectorserotype2(AAV2)expressingachimeraof mouseCTLA-4fusedwithahumanimmunoglobulin(AAV2-CTLA4IgG)andobservedtheeffectofthismoleculein C57BL/6.NODAec1Aec2 mice,ananimalmodelofpSS. Methods: Arecombinantadeno-associatedvirus-2(AAV-2)vectorwasconstructedencodingaCTLA4IgGfusion protein.TheAAV2-CTLA4IgGvectorandanAAV2controlvectorencodingbetagalactosidase(LacZ)were administeredbyretrogradecannulationofthesubmandibularglandsofC57BL/6.NODAec1Aec2 mice.Protein expressionwasmeasuredbyELISAandsalivaryglandswereassessedforinflammationandactivity. Results: RecombinantCTLA4IgGblockedB7expressiononmacrophages invitro.Invivo ,localizedexpressionof CTLA4IgGinthesalivaryglandsofC57BL/6.NODAec1Aec2 miceinhibitedthelossofsalivaryglandactivityand decreasedTandBcellinfiltrationaswellasdendriticcellsandmacrophagesintheglandscomparedwithcontrol mice.Inadditionadecreaseinseveralproinflammatorycytokinesandanincreaseintransforminggrowthfactor beta-1(TGFb1)expressionwerealsoobserved. Conclusions: ThesedatasuggestexpressionofCTLA4IgGinthesalivaryglandcandecreasetheinflammationand improvethexerostomiareportedinthesemice. Keywords: Sjgren sSyndrome,salivaryglanddysfunction,adeno-associatedvirus(AAV),CTLA4IgGfusionprotein, preventionIntroductionPrimarySjgren ssyndrome(pSS)isachronicautoimmunedisorderthatresultsinimpairedexocrinegland function.Xerostomia(drymouth)andxerophthalmia (conjunctivitissicca,dryeyes)arehallmarksofSjgren s syndrome[1].ThemechanismassociatedwithSjgren s syndromeisunclearhowever,immunologically-activated orapoptoticglandularepithelialcellsmaypresentnovel autoantigensinpredisposedindividualsdrivingautoimmune-mediatedtissueinjury[2,3].Immuneactivationis typicallypresentedasfocal,mononuclear(T,B,dentritic,andmacrophage)cellinfiltrates,proximaltothe ductalepithelialcellsandformssialadenitis[2].Lymphocyticinfiltrationsinthesalivarygland(SG)and lachrymalglands(LG)consistof60%to70%CD4+Tlymphocytes,andasubstantialnumbersofBcells,dendriticcells(DCs),plasma,andmacrophage(M )cells [2,4,5].AbnormalactivationofproinflammatoryTh1 [6,7],andTh17[8]cellsandcytokinessuchas *Correspondence:jchiorini@dir.nidcr.nih.gov Contributedequally1MolecularPhysiologyandTherapeuticsBranch,NationalInstituteofDental andCranialResearch,NationalInstitutesofHealth,10CenterDrive, MSC1190,Bethesda,MD20892,USA FulllistofauthorinformationisavailableattheendofthearticleYin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 2012Chiorinietal.;licenseeBioMedCentralLtd.ThisisanopenaccessarticledistributedunderthetermsoftheCreativeCommons AttributionLicense(http://creativecommons.org/licenses/by/2.0),whichpermitsunrestricteduse,distribution,andreproductionin anymedium,providedtheoriginalworkisproperlycited.

PAGE 2

interferong (IFNg ),interleukin-12(IL-12),IL-17were reportedinanimalmodelsofpSSandpatientsamples [7-11].Inaddition,adramaticdropinTregulatorycells (Treg)anddecreasedexpressionofTGFb 1inSGinfiltrateswasalsoreportedinpSSpatients[12].Furthermore,TGFb 1deficientmicedevelopaSjgren s syndromelikeautoimmunedisease[13]. CytotoxicT-lymphocyteantigen4(CTLA-4)isan importantimmuneregulatoryproteinanddisplaysa widerangeofactivitiesassociatedwithimmunetolerance.BycompetingwithCD28tobindB7-1/2(CD80/ CD86),CTLA4blockstheactivationofTcells,thus maintainingimmunehomeostasis[14].CTLA-4isconstitutivelyexpressedonTregcellsandalsobindstoB7 onantigen-presentingcells(APCs)toinhibitactivation ofeffectorTcells[15,16].Recentlyitisnotedthat epithelialcellsintheminorSGsofpSSpatientsexpress costimulatorymoleculesB7.1(CD80)andB7.2(CD86) [17].Correspondingly,differenthaplotypesofCTLA-4 werefoundtobeassociatedwithincreasedsusceptibility topSS[18]. Currently,arecombinantfusionproteinofCTLA4immunoglobulin(CTLA4-I g,Abatacept,Orencia)is licensedintheUnitedStatesforthetreatmentofrheumatoidarthritis[5].Abatacept,whichcontainsthe CTLA-4high-affinitybindingsiteforB7blocksB7: CD28costimulatorysignalingpathwayandisreported toshutdownactivationofproinflammatoryTcells[19] aswellasBcells,DCs,andM [20,21]. InordertostudytheaffectofCTLA4blockadeonthe sialadenitisandxerostomiaassociatedwithSjgren s syndrome,CTLA4IgGwaslocallyexpressedinthesalivaryglandsofC57BL/6.NODAec1Aec2 mice,which developaSjgren ssyndrome-likedisease.Ourfindings ofbothfunctionalandimmunologicalimprovementin themicewarrantfurtherinvestigationofCTLA4 mediatedimmunomodulation asatherapeuticpathway fortreatmentofpSSpatients.MaterialsandmethodsCelllinesHEK-293TcellsweregrowninDulbecco smodified Eagle smedium(DMEM).Mediumwassupplemented with10%heat-inactivatedfetalbovineserum(LifeTechnologies,Rockville,MD,USA),2mML-glutamine, penicillin(100U/ml),andstreptomycin(100 g/ml;Biofluids,Rockville,MD,USA)aspreviouslydescribed[22].ConstructionandtestingofAAV2-CTLA4IgGWepreviouslyreportedconstructionofAAV2-LacZ [23].Inthisstudyweusedtheextracellulardomainof mouseCytotoxicT-lymphocyteantigen4(CTLA4) coupledtohumanImmunoglobulinG(IgG)C g 1 (CTLA4IgG),kindlyprovidedbyDrToshimitsuUede (InstituteofImmunologicalScience,HokkaidoUniversity,Hokkaido,Japan)[24].Thisgenewasclonedinto therecombinantadeno-associatedvirus(AAV)plasmid containingacytomegalovirus(CMV)promoterandthe invertedterminalrepeat(ITRs)sequencesforAAVserotype2(AAV2).Theplasmid(AAV2-CTLA4IgG)was transfectedintoHEK-293Tcellsandexpressionofthe proteininthemediawasdeterminedbywesternblottingafterelectrophoresisinreducingconditionsusing anti-mCTLA4Ab(R&Dsystems,Minneapolis,MN, USA).CompetitiveinhibitionofB7associationbyCTLA4IgG in vitroMousemacrophages(CRL-2751,ATCC)weregrownin DMEMwith4mML-glutamine,1.5g/Lsodiumbicarbonate,4.5g/Lglucose(Biofluids,Rockville,MD,USA), 10%fetalbovineserum,and20%LADMACconditioned media(producedfromtheLADMACcellline(CRL2420)at37Cinahumidified,5%CO2atmosphere, incubator.1105cells/wellwereplacedinroundbottom96-wellplatesandspundownat1500rpmina benchtopcentrifugeat4C.Thecellswerethenwashed twicewithPBS(pH7.4,0.05%Tween20)andincubated for1hat37CwitheithermediumfromcontrolHEK293TcellsorfromHEK-293Tcellstransfectedwith AAV2-CTLA4IgG.Followingadditionalwashes,the cellswereincubatedinthedarkwith0.5to1 g/mlof ArmenianhamsterIgGFITC-conjugatedantiB7-1 (SantaCruzBiotechnology,SantaCruz,CA,USA)in blockingsolution(PBS,pH7.4,0.5%BSA)at4Cfor40 min.Thecellswerethenwashedandanalyzedbyflow cytometryassay.VectorproductionTogenerateAAV2vectors,weusedtheadenoviral helperpackagingplasmidpDG.Fifteen-cmplatesof approximately40%confluentHEK-293TcellswerecotransfectedwitheitherAAV-LacZorAAV-CTLA4IgG accordingtostandardizedmethods[25].Clarifiedcell lysateswereadjustedtoarefractiveindexof1.372by additionofCsCl,andcentrifugedat38,000rpmfor65 hat20C.Equilibriumdensitygradientswerefractionatedandfractionswitharefractiveindexof1.369to 1.375werecollected.Theparticletiterwasdetermined byQ-PCRandthevectorwasstoredat-80C.Onthe dayofvectoradministrationtoC57BL/6.NODAec1Aec2 mice,thevectorwasdialyzedfor3hagainstsaline.AnimalsThreefemaleandtenmaleC57BL/6.NODAec1Aec2 mice,agedsixweeks,werebredandmaintainedatthe animalfacilityoftheDepar tmentofPathology,UniversityofFlorida,asdescribedpreviously[26].BaselineYin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page2of11

PAGE 3

salivaandtearflowwascollectedfrommicewhenthey weresixweeksold.Genetherapystudies,asdescribed herein,wereapprovedbytheUniversityofFlorida s IACUCandIBC.AAV2vectoradministrationMicewererandomlygroupedandvectorsweredeliveredintothesubmandibularglandsbyretrograde instillationaspreviouslydescribed[22](AAV2-LaZ:1 female,5malesandAAV2-CTLA4IgG:2females,5 males).Aspreviouslyreported,thevectorwaswelltoleratedwithnovectorrelatedinflammation[22,27]. Briefly,eight-week-oldmiceweremildlyanesthesized withketamine(100mg/ml,1ml/kgbodyweight;Fort DodgeAnimalHealth,FortDodge,IA,USA)andxylazine(20mg/ml,0.7ml/kgbodyweight;PhoenixScientific,StJoseph,MO,USA)solutiongivenby intramuscularinjection(IM).TenminutesafterIM injectionofatropine(0.5mg/kgBW;Sigma,StLouis, MO,USA),micewereadministered50 lAAV2vector intobothsubmandibularglandsbyretrogradeductal instillation(11010particles/gland)usingathin cannula.DetectionofCTLA4IgGexpressioninsalivaryglandsand serumfromC57BL/6.NODAec1Aec2 miceToconfirmthestableexpressionofCTLA4IgG invivo afterlocaldeliveryintheSGsfromC57BL/6.NODAec1Aec2 mice,homogenatesofSGswerepreparedas describedpreviously[7].TotalproteininthesupernatantwasdeterminedwithBCA proteinassaykit (Pierce,Rockford,IL,USA)accordingtothemanufacturer sinstructions.Bloodwascollectedbycardiac punctureatthetimeofsacrificingandcollectedin microcentrifugetubes.Serumwasseparatedbycentrifugationfor20minat2000gandstoredat-80C. CTLA4IgGwasdetectedbysandwichELISA.A96wellplate(Nunc,Rochester,NY,USA)wasincubated overnight(O/N)with0.4 g/mlcaptureantibody,goat anti-mouseCTLA-4Ab(R&D,Minneapolis,MN, USA)incarbonate/bicarbonatebuffer(pH9.5).The nextday,wellswereblockedandincubatedwith100 Lofappropriatelydilutedstandardcontrol(0.0850 g/mlrCTLA4,R&D,Minneapolis,MN,USA)or serum,undilutedSGhomogenatesfor2haccording totheproductinstructions.Followingthreewashings, thewellswereincubatedwitha1:5,000dilutionof peroxidaseconjugatedaffinitypurifiedgoatantihumanIgG(JacksonImmunoResearch,WestGrove, PA,USA)for1hatRT.Substratereactionwasdevelopedfollowingthemanufacturer sprotocolandthe platewerereadatOD450nmusingaMicroplate readermodel680(Bio-RadLaboratories,Hercules, CA,USA)[7].MeasurementofsalivaryandtearflowratesPilocarpinestimulatedsalivaflowrate(SFR)andtear flowrate(TFR)collectionwasperformedasdescribed previously[8]attheindicatedtimepoints.Briefly,individualnon-anesthetizedmicewereweighedandgiven ani.p.injectionof100 lofPBScontainingamixture ofisoproterenol(0.02mg/ml)andpilocarpine(0.05mg/ ml).Salivawascollectedfromtheoralcavityofindividualmicefor10min.Atweek30,tearvolumesfrom individualanimalweremeasuredafteri.p.injectionof pilocarpine(4.5mg/g[BW])for20sanddetermined usingaphenolredthread(Zone-Quick,FCIOphthalmics,Pembrooke,MA,USA),amodifiedversionofthe Schirmertestasdescribed[8].SFRandTFRwerethen calculatedpergrambodyweight.DeterminationofautoantibodiesAttheendofthestudy,serumwascollectedfrom30week-oldC57BL/6.NODAec1Aec2 mice.AnELISAwas developedasdescribedpreviously[7]todetectautoantibodiesagainstSSA/Ro[multipleantigenicpeptide (MAP)-Ro273](UniversityofOklahomaHealthSciences MolecularBiologycoreFac ility,OklahomaCity,OK, USA).AutoantibodiesagainstSSB/La(totalIg)were measuredbyacommerciallyavailableELISAkit(Alpha DiagnosticInternational,SanAntonio,TX,USA) accordingtothemanufacturer sprotocol.HistologicalassessmentofsalivaryglandsFollowingeuthanasia,wholeSGsweresurgically removedfromeachmouseandplacedin10%phosphate-bufferedformalinfor24hforhematoxylinand eosin(H&E)stainingasde scribedpreviously[10]. Stainedsectionswereobservedunderamicroscopefor glandularstructureandleukocyteinfiltration.Unstained sectionswereusedforimmunofluorescenceandimmunochemistrystaining(below).ImmunofluorescencestainingforCD3+TcellsandB220+B cellsImmunofluorescencestainingforTandBcellsforthe infiltrationsintheSGswasdoneaspreviouslydescribed [8].Brieflyhistologicalsectionsofsalivaryglandswere incubatedwithratanti-m ouseB220(BDPharmingen, SanJose,CA,USA)andgoatanti-mouseCD3(Santa CruzBiotechnology,SantaCruz,CA,USA),followedby incubationwithTexasRed-conjugatedrabbitanti-rat IgG(Biomeda,FosterCity,CA,USA)andFITC-conjugatedrabbitanti-goatIgG(Sigma-Aldrich,St.Louis, MO,USA).TheslidesweremountedwithDAPImountingmedium(VectorLaboratories,Burlingame, CA,USA).Sectionswereobservedat200magnificationusingaZeissAxiovert200Mmicroscope,and imageswereobtainedwithAxioVs40software(Ver.Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page3of11

PAGE 4

4.7.1.0,Zeiss)(CarlZeiss,Thornwood).Thenumberof lymphocyticfoci(LF)ineachsectionwasblindlyenumeratedbythreeindividualinvestigators.Thenumberof BandTcells,andtotalnumberofnucleiineachLF weredeterminedusingMayachitraimagesoftware (Mayachitra,Inc.,SantaBarbara,CA,USA).ImmunohistochemicalstainingforCD11candF4/80in salivaryglandsParaffin-embeddedSGsweredeparaffinizedbyimmersioninxylene,followedbyantigenretrievalwith10mM citratebuffer,pH6.0.Tissuesectionswerethenincubatedovernightat4Cwitha nti-CD11coranti-F4/80 antibody(SantaCruzBiotechnologySantaCruz,CA, USA).TotalrabbitIgGwasusedasanisotypecontrol. TheslideswereincubatedwithbiotinylatedgoatantirabbitIgGsecondaryantibodyfollowedbyhorseradish peroxidase-conjugatedstrep avidinincubationusingthe VectastainABCkit.Thestainingwasdevelopedby usingdiaminobenzidinesubst rate(VectorLaboratories, Burlingame,CA,USA),and counterstainingwasperformedwithhematoxylin.Sectionswerephotographed at200magnificationusingaZeissAxiovert200M microscope,andimageswereobtainedwithAxioVs40 software(Ver.4.7.1.0,Zeiss)(CarlZeiss,Thornwood). ThenumberofCD11corF4/80-positivecellswas countedbythreedifferentexaminersandthemeanof threecountingweredetermined.DetectionofcytokinesfromimmunecellculturesandSG homogenatesCytokinesfromspleencellanddraininglymphnodes (DLN)cellculture,serum,andhomogenatesofSGs weredetectedasdescribedpre viously[28].Brieflycells fromspleenandsubmadibularsalivarygland(SMGs) associatedDLNsobtainedfromtreatedmicewereisolatedrespectivelyandsamplesfrommiceineachgroup werepooledandculturedin24-wellplatesat5106cells/mlRPMI-1640medium(Invitrogen,Carlsbad,CA, USA),containingHL-1serumreplacement(Cambrex Bioscience,Walkersville,MD,USA),withorwithout1 g/mlConcanavalinA(ConA,Sigma-Aldrich,StLouis, MO,USA).Supernatantswerecollectedafter48hincubation.SerumandSMGhomogenateswerepreparedas describedpreviously[7,28]andthreesamplesfrom representativemiceineachgroupwereusedfor detection. Murineinterleukin-6(IL-6 ),tumornecrosisfactora (TNF-a ),IL-12p70,interferong (IFNg ),IL-18,IL-17, IL-23,transforminggrowthfactorb 1(TGFb 1),mast cellproteinase-1(MCP-1),andmacrophageinflammatoryproteins-1(MIP-1)weremeasuredusingamultiplexsandwich-ELISAassay(AushonBiosystemBillerica, MA,USA).Duplicatesforeachsampleweretestedin threedilutionsandthemeanvaluesoftheduplicates fromtheoptimaldilutionwerereported[28].StatisticalanalysisMann-WhitneyUtestwasusedtoanalyzedifferencesof cytokineproductioninserum.Unpairedstudentt-test wasusedtoanalyzedifferencesbetweentwoexperimentalgroupsinotherassays.Allanalyseswereperformed withGraphPadPrismstatisticalsoftware(GraphPad SoftwareInc.version4.02,LaJolla,CA,USA)usinga P value 0.05asstatisticallysignificant.ResultsDetectionofCTLA4IgGandbindingtoB7 invitroPriortoanalyzingstableexpressionofCTLA4IgGfrom AAV2-CTLA4IgGintheSGsofC57BL/6.NODAec1Aec2 mice,weconfirmedboththeexpressionand thebiologicalactivityofthefusionproteinbywestern blot,andbyblockingtheB7:CD28pathway invitro respectively. FusionoftheCg 1domainofIgGtothebinding domainofCTLA4resultedinachimericproteinof approximately62kDa.Secretionwasconfirmedbywesternblotofthecellculturemediafromtransfectedcells (Figure1A). Macrophages,likedendriticcells,areoneoftheantigenpresentingcells(APCs)thatexpressthecostimulatorymoleculeB7.Totesttheabilityoftherecombinant CTLA4IgGtobindandblockB7detection,supernatant fromCTLA4IgGexpressingcellswaspreincubatedwith macrophagesandthenB7quantifiedbyflowcytometry assay.Comparedtomacrophagesincubatedwithout CTLA4IgG,unboundanddetectableB7expressionon themacrophagesincubatedwithCTLA4IgGwas decreased,suggestingbindingbetweenB7and CTLA4IgG.Invivo expressionofCTLA4IgGfollowingcannulation withAAV2-CTLA4IgGinC57BL/6.NODAec1Aec2 miceSalivaryglandinfiltratinglymphocytesinC57BL/6. NODAec1Aec2 arefirstdetectedbetween8and12 weeksofage.However,microarrayanalysisindicates thatadhesionmoleculesaswellasgenesassociatedwith macrophagesanddendriticcellsareupregulationas earlyas8weeksofage.Priorto8weeksSGsarenot consideredfullymature.Thus,wechosetocannulate theglandsat8weekswhichwouldbeconsideredan ourearlystageofdisease[29].Aspreviouslyreported, cannulationofthesemicewithAAVvectorswaswell toleratedandnovectorrelatedinflammationwas observed[22,27].Toconfirmthestableexpressionof CTLA4IgG invivo afterlocaldeliveryofAAV2CTLA4IgGtotheSGsofC57BL/6.NODAec1Aec2 mice,SGhomogenatesandserumwereobtainedattheYin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page4of11

PAGE 5

endofthestudy(30weeks)andpooledaccordingto eachgroup.Usingasandwich-ELISAtodetectthe recombinantchimericprotein(mouseCTLA4and humanIgG),micethatreceivedAAV2-CTLA4IgGhad muchhigherlevelsofCTLA4IgG(44.50.76pg/mlin SGand7.480.70pg/mlinserum,meanSD)in boththeirSGandserumcomparedwithmicethat receivedvectorexpressingLacZ(0.390.02pg/mlin SGand0.620.01pg/mlinserum)( P =0.0003and P =0.0102,respectively,inSGandserum)(Figure2).In agreementwiththelocaldeliveryofvector,thelevelof expressionintheSGhomogenateswaselevatedcomparedwithserumintheAAV2-CTLA4IgG-treated mice.LocalexpressionofAAV2-CTLA4IgGpreventstheagedependentlossofsalivaryglandactivityinC57BL/6.NODAec1Aec2 miceTobetterunderstandtheeffectofCTLA4IgGonSG function,stimulatedsalivaflowwasmeasuredinboth treatedandcontrolmiceovertime.Inagreementwith previousstudies[26],micetreatedwiththecontrol LacZexpressingvectorshowedasignificantdecreaseof salivaflowby16weeks(4.250.64 L/g10min),comparedwiththebaselineflowat6weeks(6.100.30 L/ g10min),whichcontinuedtodeclineovertime[8]. MicethatreceivedAAV2CTLA4IgGvectorinitiallyalso showedsomedecreaseinsalivaflowat16weeks(5.13 1.22 L/g10min),butitwasnotstatisticallysignificant comparedwiththe6-weekbaseline( P =0.2057).However,by22weeksthesalivaflowfromtheCTLA4IgG micehadrecoveredtonearbaselinevalues(6.130.92 L/g10min),whichwassustainedfortheremainderof thestudy,andwasstatisticallydifferentcomparedwith theAAV2-LacZ-treatedgroupat30weeks( P =0.0222). ThesedatasuggestthatexpressionofCTLA4IgGinthe SGsofC57BL/6.NODAec1Aec2 micecaninhibitthe lossofSGfunction(Figure3A).SalivaryglandtransductionwithAAV2CTLA4IgGhad onlyminimalaffectonlachrymalglanddysfunctionin C57BL/6.NODAec1Aec2 micePreviousresearchhassuggestedthatfollowingcannulationoftheSG,greaterthan90%oftheAAV2vector remainsinthegland[27].Similarlyhigherlevelsofthe expressioncanalsobedetectedlocallyinthegland homogenatescomparedwithcirculatinglevels.Inorder totestifthecirculatinglevelsofCTLA4IgGweresufficienttohaveaneffectonothersecretoryepitheliasuch asthelossoflachrymalglandfunctionintheC57BL/6. Figure1 Invitro expressionandactivityofCTLA4IgG (A) Invitro expressionofCTLA4IgGwasdetectedbywesternblotofmediafrom AAV2-CTLA4transfectedcells(lane3).Asacontrol,purifiedrecombinantmouseCTLA4/Fcwasalsorunonthegel(lane2). (B) Biologicalactivity ofCTLA4IgG,basedonitsabilitytobindandblockB7.1,wasdeterminedbyincubatingwitheithermediumfromnaveHEK-293Tcells(column 1)orfromcellstransfectedwithAAV2CTLA4(column2).UnboundB7.1wasthentestedbyflowcytometryusinganantibodytoB7.1.Data shownismeanfromthreeindependentexperiments(asterisk, P =0.0400).Unpairedstudent-ttestwasusedinthisanalysis. Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page5of11

PAGE 6

NODAec1Aec2 mice,wemeasuredstimulatedtearflow attheendofthestudy.CTLA4IgG-treatedmicehadan overallincreaseintearflowcomparedwiththeLacZexpressinggroup,butwasnotsignificantlydifferent( P =0.1316)(Figure3B).CTLA4IgGexpressiondoesnotchangeautoantibody levelsinC57BL/6.NODAec1Aec2 miceToobservetheeffectofCTLA4IgGontheregulationof systemicBcellactivation,wemeasuredanti-Ro(SSA) andanti-La(SSB)autoantibodies,whicharehighly Figure2 Invivo expressionofCTLA4IgGinsalivaryglandsfromC57BL/6.NODAec1Aec2 mice .AsandwichELISAwasdevelopedtodetect expressionofmouseCTLA4andhumanIgG(CTLA4IgG)chimerasinhomogenatesofsubmandibularsalivaryglands( A )andserum( B )(Materials &Methods).DatashowthemeanSEMfromeachgroup.MicecannnulatedwithAAV2-CTLA4IgG( n =6,pooledintotwosamples/group)had significantlevelsofCTLA4IgGproteininthesalivaryglandscomparedwithmicethatreceivedAAV2-LacZ( n =7,pooledintotwosamples/ group),(twoasterisks, P =0.0003)andserum(asterisk, P =0.0102)Unpairedstudent-ttestwasusedinthisanalysis. Figure3 StimulatedsalivaandtearflowintreatedC57BL/6.NODAec1Aec2 mice .Salivaandtearflowwerecollectedasdescribedinthe Materials&Methodssection.ThedatashownrepresentthemeanSEMflowpergroup( n =6inAAV2-LacZgroupand n =7inAAV2CTLA4IgGgroup).Unpairedstudentt-testwasusedinthisanalysis. (A) MicetreatedwithvectorexpressingCTLA4IgGshowedprotectionfrom lossofglandactivity.Salivawascollectedovera10-minperiodafterstimulationwitha100 lofPBScontainingamixtureofisoproterenol(0.02 mg/ml)andpilocarpine(0.05mg/ml)andtearflowwerecollectedovera20-speriodafterinjectionofpilocarpine(4.5mg/kgbodyweight). AAV2-LacZmiceshoweddecreasedsalivaonweeks16,22,26,and30(asterisk, P =0.0428,0.0217,0.0292,and0.0128,respectively),compared withthebaselinesalivacollectiononweek6( n =9,5.9330.2969).AAV2-CTLA4IgG-treatedmicehadaslightdecreaseofsalivabutthiswas notsignificantat16weeks( P =0.2057).SalivaflowofCTLA4IgG-treatedmiceincreasedtobaselinelevelby22weeks(6.130.92 L/g10min). CTLA4IgG-treatedmicehadincreasedsalivaflowcomparedwithLacZ-treatedmiceby30weeks( P =0.0232). (B) DeliveryofAAV2-CTLA4IgG resultedinanincreaseintearflow(meanSEM)by30weekscomparedwithcontrolmice,butthiswasnotsignificant( P =0.1316). Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page6of11

PAGE 7

correlatedwithpSS[30].Minimalchangesinanti-Ro andanti-LatiterweredetectedintheCLTA4IgG-treatedmicecomparedwiththeAAV2-LacZ-treatedmice (Figures4Aand4B).SalivaryglandtransductionwithAAV2CTLA4IgGcan decreaseinfiltratingTandBcells,DCs,andM TodeterminetheeffectofCTLA4IgGonlymphocyte foci(LF)intheSGs,wedetectedthenumberofLFas wellasthenumberofTandBcellswithinthegland byimmunofluorescencestainingofCD3andB220, respectively(Figures5A,B,C,and5D).Thenumberof LFweredecreasedintheSGsofCTLA4IgGmice(0.71 LF/pergland)comparedwithcontrolLacZmice(2.16 LFs/pergland).Furthermore,thenumberofTandB cellspresentintheLFalsodecreased.Althoughthe decreaseinTcellswassignificant,thechangeinB cellswasnotstatisticallysignificantcomparedwith controlLacZ-treatedmice( P =0.0464and P =0.3024 foranalysisofTandBcells,respectively)(Figures5C, D,Eand5F). AnincreaseinDCsandmacrophageshasalsobeen reportedintheSGsofpSSpatients[31].Thenumber ofDCsandM cells(detectedbystainingforCD11c+ DCsandF4/80+,respectively)wassignificantly decreasedintheCTLA4IgG-treatedgroupcompared withtheLacZcontrolgroup(DCs:13.332.78/gland inLacZgroup vs .2.140.70/perglandinCTLA4IgG mice, P 0.01.M :14.890.11/glandinLacZgroup vs .3.842.31/perglandinCTLA4IgGmice, P 0.0001)(Figure5E,F,G,H,I,J,Kand5L).These dataindicatethatlocalexpressionofCTLA4IgGcan inhibitT-cellaccumulationintheSG,aswellasDCs andM .CTLA4IgGexpressiondecreasedproinflammtorycytokines andincreasedTGFb 1insalivaryglandassociatedlymph nodesToinvestigatecytokineproductionafterCTLA4IgG expression,wemeasuredthelevelsofcytokineassociatedwithdifferentpopulationsofTcellsormacrophagesinbothspleenandserumaswellaslocallyin theSGandassociateddraininglymphnodes(DLN). InSGhomogenates,onlyadecreaseinIL-6was observedintheAAV2-CTLA4IgG-treatedmice(median =169.60pg/ml)comparedwithAAV2-LacZcontrols (median=86.51pg/ml),whichwasnotstatisticallysignificant( P =0.9062,datanotshown).Interestingly, TGFb 1productionincreasedintheCTLA4IgGgroup comparedwithcontrolLacZ-treatedmice,howeverthe increasewasnotstatisticallysignificant(median= 1208.70pg/ml vs.median=804.53pg/m l,respectively) ( P =0.093,datanotshown).Inthepooledcellculture mediaoftheDLNcellsassociatedwiththeSG,ageneraldown-regulationinpro inflammatorycytokinewas observedintheCTLA-4IgG-treatedmicecompared withcontrolLacZmice.Th1cytokines(IL-12,IFNg andIL-18)andTh17cytokine(IL-23)werealldownregulated.Again,TGFb 1wasstrikinglyup-regulated.In addition,non-specificproin flammatorycytokines,IL-6 andTNFa ,aswellaschemokinesMCP-1andMIP-1 a whicharemainlyreleasedfrommacrophages,were decreased(Table1).Littlec hangewasdetectedinTh2 cytokinessuchasIL-4,IL-5,andIL-13afterlocal expressionofCTLA4IgG(datanotshown).These changessuggestthatCTLA4IgGexpressioncanreduce proinflammatorycytokinesreleasedbyTh1,Th17cells, DCs,andmacrophages,whilestimulatingproductionof anti-inflammatorycytokinessuchasTGFb 1.This Figure4 Serumanti-nuclearantibodyproductionsinC57BL/6.NOD-Aec1Aec2 mice .Serumsampleswereanalyzedforanti-Ro(SSA) (A) and anti-La(SSB) (B) antibodyexpressioninserumfromAAV2-LacZ( n =6)andAAV2-CTLA4IgG( n =7)treatedmicebyELISA.Thedatashown representthemeanSEMinODorU/mlfromduplicatetestsofpooledsamplesfromeachgroup.Unpairedstudent st-testwasusedfor statisticalanalysis.Nostatisticallysignificantdifferencewasdetected( P =0.9586and0.4158,respectively). Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page7of11

PAGE 8

Figure5 Histologicalexaminationofsalivaryglands .Salivaryglandhistologywasexaminedattheendofthestudy(30weeksofage).CD3 +TandB220+Bcellimmunofluorescencestaining,aswellasCD11candF4/80immunochemistrystainingfordendriticandmacrophagescells respectivelyweredoneasdescribedinMaterialsandMethods.Panelsshowrepresentativeimmuno-fluorescencestainingofsalivaryofBandT cellsinSGsfrommicecannulatedwithAAV2-LacZ( n =6)orAAV2-CTLA4IgGvector( n =7) (A,B,andC) (Bluearrows)andenumeration(mean SEM) (D) ofBandTcellsinSGsfromLacZ-andCTLA4IgG-treatedmice;immunohistochemicalstainingandenumeration(meanSEM)of CD11c+DCs (E,F,G,andH) andF4/80+macrophages( I,J,K,andL) (Blackarrows)inSGsfromLacZ-andCTLA4IgG-treatedC57BL/6.NODAec1Aec2 mice.AstatisticaldecreaseintheenumerationofbothTcellswasshownintheSGsfromCTLA4overexpressingmicecomparedto theLacZ-treated( P =0.0464).Nostatisticalsignificancebutatrendwasshown( P =0.3024)fordecreasetrendofBcells.SignificantdownregulationofbothCD11c+dendriticcellsandF4/80+macrophageswasseenintheSGsfromCTLA4IgG-treatedmicecomparedwithcontrol (twoasterisks, P 0.01).Unpairedstudent-ttestwasusedintheanalysis. Table1Cytokineproductionlocalandsystemicimmunesysteminvectortreatedmice(pg/ml)DLNcells Spleencells Serum LacZCTLA4IgGLacZCTLA4IgGLacZ CTLA4IgG Th1IL-12p70120.00 4.60.2088.515.8 88.515.8 IFNg 3.80.00 122115.0872.61,276.8457.2371.8 IL-18110.00 160.00 694562 394.10 Th17IL-17N/AN/A2.10.00 2.83.3 N/A IL-2314N/A 78.236.10 335.6365.7101.99 Treg-orSGepithelialcellsTGF-b1N/A41,410 2,0841,3841,501,176277,2491,260,620289,478 Non-specific(Macrophages)IL-624521,688 2,5572,4073091,241 289355 TNF-a 4327 98120 3783 41142 Chemokines MCP-1102 4443 6319 6626 MIP-1a 224130 357237 20.2 2.52.5Serum,splenocytes,andsalivaryglandDLNswerecollectedattheendofthestudy.SplenocytesandDLNcellswerepooledaccordingtovectortreatment group.CulturesupernatantswerecollectedfollowingincubationwithorwithoutConAfor48h.Culturesandserumwerethenanalyzedforlevelsofthe indicatedcytokines(inpg/ml)bymulti-cytokineassayinduplicate.Forcellcultures,valuesarethemeanofduplicatetestsofConAtreatedcellssubtractedfrom mediaalone.Forserum,thedatashownwerethemedianSDofeachgroupofmice(AAV2-LacZ[ n =6]andAAV2-CTLA4IgG[ n =7],respectively].MannWhitneyUtestwasusedtoanalyzedifferencesofcytokineproductioninserum. :ProductionofcytokinesintheAAV2-CTLA4IgGgroupis 50%higherthanin AAV2-LacZgroup; :ProductionofcytokinesintheAAV2-CTLA4IgGgroupis 50%lowerthantheAAV2-LacZgroup.Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page8of11

PAGE 9

furthersupportsthefindingofreducedinflammation withCTLA4IgGtreatment.EffectofCTLA4IgGonregulationofsystemicTcell responseintheC57BL/6.NODAec1Aec2 miceTotestforchangesinthesystemicimmunesystem, cytokineswerealsomeasuredinserumandinspleen cellcultures.Widevariationwasseenincytokinevalues inserum,andnoneofthecytokinelevelsfromthe CTLA4IgGandLacZgroupsshowedstatisticalsignificance.However,adecrease(achangeinthemedianof 50%)inamajorityofcytokinesassociatedwithTh1 andTh17cells,suchasIFNg ,IL-18,IL-17,andIL-23, wasseenintheserumofAAV2-CTLA4IgG-treated micecomparedwithAAV2-LacZ-treatedmice.Inaddition,productionofIL-12,IL-18,IL-17,andIL-23from splenocyteswasdown-regulatedintheAAV2CTLA4IgG-treatedgroupcomparedwiththeAAV2LacZ-treatedmice.Unlikethelocalimmuneresponse seenintheSGassociatedDLN,minimalchangeinnonspecificcytokines,chemokines,orTGFb 1wasdetected inserumorculturedsplenocytes.Thesedataimplythat CTLA4IgGexpressioncana lsodecreaseproinflammatorycytokinesintheperipheralimmunesystem,followinglocalSGgenetransferinC57BL/6.NODAec1Aec2 mice(Table1).DiscussionTheblockadeofCD28co-stimulationbyrecombinant CTLA4IgG(abatacept)hasdemonstratedclinicalutility inthetreatmentofrheumatoidarthritis[14].Inour study,localexpressionofCTLA4IgGbygenetransferto theSGsofC57BL/6.NODAec1Aec2 mice,apSSanimal model,resultedinadecreaseinthesialoadenitisand improvementinglandfunctioncomparedwithmice thatreceivedacontrolvector. Theadvantageoflocalizedgenetransferistodirect theexpressionofthetherapeuticmoleculetothesiteof maximumeffectwhileminimizingthesystemiccomplicationsthatcanbeassociatedwithofftargeteffects. Usingthisapproachwewereabletoachievemuch higherlocalconcentrationsofCTLA4IgGinthesalivary glandscomparedtocirculatinglevelsintheserum.Our datafurtherconfirmthatductalcellswithinthegland representagooddepotsiteforproductionofrecombinantproteins[32].Indeed,previousexperimentshave demonstratedexpressionfromsalivaryglandductalcells forthelifeoftheanimal[33]. InbothpatientsandC57BL/6.NODAec1Aec2 mice, activatedCD4+TlymphocytesincludingTh1andTh17 cellsinfiltratethesalivaryandlachrymalglands,and produceavarietyofproinflammatorycytokines,suchas IFNg andIL-17,whichmaytriggerglanddamageand representacrucialelementinthepathogenesisofpSS [2,34].Althoughnotstatisticallysignificant,wedid detectadecreaseinTh17cytokineinboththeDLN andspleenfollowingexpressionofCTLA4IgG,suggestingacorrectiveshiftinthiscriticalcellpopulation. BesidesthenegativeeffectonTcellsasaresultof blockadeoftheB7:CD28costimulatorypathway[19],it isalsonotedthatrecombinantCTLA4IgGmaydirectly orindirectlydeactivateDCs,macrophagesandBlymphocytes[15,21].OurdataindicatethatinC57BL/6. NODAec1Aec2 mice,CTLA4IgGexpressionresultsina decreaseinTandBlymphocytesaswellasDCsand macrophagesintheSGthatisaccompaniedbyadownregulationinproinflammatorycytokines.Ourfindingis inagreementwithpreviousreportsontheeffectof CTLA4IgGinotherautoimmuediseasemodel[20,21]. Interestingly,asignificantincreaseinTGFb 1expressioninboththeSGandtheDLNswasobserved.The increaseinTGFb 1expressionmayberelatedtoan increaseinnTregornegativeregulationofepithelial cellsbyCTLA4IgG[15].Inadditiontoitsroleinthe immunesystem,TGFb 1expressionwasfoundtobe importantinmaintainingepit helialtightjunctions,an importantcomponentinthefluidmovementofSGs [35]andthereforemaybedirectlyrelatedtothe improvementinsalivaflow. OurstudysuggestsanimprovementofSGfunction, whichcouldresultfromtheinhibitionofsialadenitis afterlocalexpressionofCTLA4IgG.Thissuggeststhat localdeliveryofAAV2-CTLA4IgGisapromisingtreatmentofpSS.Inaddition,someimprovementinlachrymalglandwasalsoobserved.Thisdifferenceislikely relatedtothelowercirculatinglevelsofCTLA4IgGin theserumcomparedwiththelevelsinthesalivarygland. Despitethepositiveresultsachievedinthisstudy,thecirculatinglevelsofCTLA4IgGarewellbelowthoseclinicallyusedwithabatacept(ht tp://packageinserts.bms. com/pi/pi_orencia.pdf).Furtherincreasesinthedoseof vectorortheuseofvectorswithimprovedgenetransfer activityinthesalivaryglandarelikelytoresultinhigher circulatinglevelsandmayhaveamoresignificantimpact onextraglandularmanifestationsofSjgren ssyndrome. Genetherapyisstillconsideredanexperimentalprocedure.However,todatemo rethan200clinicaltrials havebeenconductedandrecentlymanyareshowing promisingresultsintreatinghemophilia,cancer,immunodeficiencies,andblindness.Anongoingtrialtargeting thesalivaryglandsisalsoreportingpositiveresultssuggestingthatgenetransfertothesalivaryglandispossible[36].Insummary,ourdatasuggestthatinhibitionof thecostimulatorypathwayCD28byexpressionof CTLA4IgGlocallyinthesalivaryglandcanbeauseful approachforreducingtheinflammationandimproving thesecretoryactivityassociatedwithSjgren s syndrome.Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page9of11

PAGE 10

ConclusionsOurdatasuggestexpressionofCTLA4IgGcanreduce thesialadenitisandimprovesecretoryactivityina mousemodelofpSS.Inadditiontoidentifyinganovel interventioninpSS,ourfindingssupporttheimportance ofco-stimulatorypathwaysasatherapeutictargetofthe disease.Abbreviations AAV2:adeno-associatedvirusvectorserotype2;ANA:antinuclearantibodies; APC:antigen-presentingcell;CMV:cytomegalovirus;CTLA-4:CytotoxicTlymphocyteantigen4;CTLA4-IgG:CTLA4-immunoglublin;DMEM:Dulbecco s modifiedEagle smedium;IFN:Interferon;IL:interleukin;IM:intramuscular injection;ITRs:invertedterminalrepeat;LF:lymphocytefoci;LG:lachrymal glands;MAP:multipleantigenicpeptide;MCP-1:mastcellproteinase-1;MIP1:macrophageinflammatoryproteins-1;pSS:primarySjgren ssyndrome; SG:salivarygland;TGF1:transforminggrowthfactor1;TNF:tumor necrosisfactor-alpha;Treg:Tregulatorycells. Acknowledgements TheauthorsthankDrGaborGIlleiforcriticalreviewandhelpfuldiscussion ofthismanuscript. Authordetails1MolecularPhysiologyandTherapeuticsBranch,NationalInstituteofDental andCranialResearch,NationalInstitutesofHealth,10CenterDrive, MSC1190,Bethesda,MD20892,USA.2DepartmentofOralBiology,Collegeof Dentistry,UniversityofFlorida,Gainesville,Florida.3Sectionof Immunopathogenesis,InstituteofImmunologicalScience,Hokkaido University,Sapporo,Hokkaido060,Japan. Authors contributions Allauthorswereinvolvedindraftingthearticle,revisingit,andmade importantintellectualcontributions.Allauthorsapprovedthefinalversion. DrChiorinihadfullaccesstoallthedatainthestudyandtakes responsibilityfortheintegrityofthedataandaccuracyofthedataanalysis. HY,CQN,ABP,andJACwereresponsibleforthestudyconceptanddesign. HY,CQN,andYSwereresponsiblefordataacquisition.HY,CQN,YS,andJAC wereresponsiblefortheanalysisandinterpretationofthedata. Competinginterests ThisworkwassupportedbyanNIHNIDCRintramuralresearchgranttoJAC. Noneoftheauthorshaveafinancialdisclosure. Received:10June2011Revised:21February2011 Accepted:27February2012Published:27February2012 References1.FoxE,KhaliqAA,SarwarM,StricklandGT: Chloroquine-resistant Plasmodiumfalciparum:nowinPakistaniPunjab. Lancet 1985, 1 :1432-1435. 2.VoulgarelisM,TzioufasAG: Pathogeneticmechanismsintheinitiation andperpetuationofSjogren ssyndrome. NatRevRheumatol 2010, 6 :529-537. 3.XanthouG,TapinosNI,PolihronisM,NezisIP,MargaritisLH, MoutsopoulosHM: CD4cytotoxicanddendriticcellsinthe immunopathologiclesionofSjogren ssyndrome. ClinExpImmunol 1999, 118 :154-163. 4.SkopouliFN,FoxPC,GalanopoulouV,AtkinsonJC,JaffeES, MoutsopoulosHM: Tcellsubpopulationsinthelabialminorsalivary glandhistopathologiclesionofSjogren ssyndrome. JRheumatol 1991, 18 :210-214. 5.GenoveseMC,BeckerJC,SchiffM,LuggenM,SherrerY,KremerJ,BirbaraC, BoxJ,NatarajanK,NuamahI,LiT,ArandaR,HagertyDT,DougadosM: Abataceptforrheumatoidarthritisrefractorytotumornecrosisfactor alphainhibition. NEnglJMed 2005, 353 :1114-1123. 6.BombardieriM,BaroneF,PittoniV,AlessandriC,ConigliaroP,BladesMC, PrioriR,McInnesIB,ValesiniG,PitzalisC: Increasedcirculatinglevelsand salivaryglandexpressionofinterleukin-18inpatientswithSjogren s syndrome:relationshipwithautoantibodyproductionandlymphoid organizationoftheperiductalinflammatoryinfiltrate. ArthritisResTher 2004, 6 :R447-456. 7.VostersJL,Landek-SalgadoMA,YinH,SwaimWD,KimuraH,TakPP, CaturegliP,ChioriniJA: Interleukin-12inducessalivaryglanddysfunction intransgenicmice,providinganewmodelofSjogren ssyndrome. ArthritisRheum 2009, 60 :3633-3641. 8.NguyenCQ,HuMH,LiY,StewartC,PeckAB: Salivaryglandtissue expressionofinterleukin-23andinterleukin-17inSjogren ssyndrome: findingsinhumansandmice. ArthritisRheum 2008, 58 :734-743. 9.WuAJ,ChenZJ,BaumBJ,AmbudkarIS: Interferon-gammainduces persistentdepletionofinternalCa2+storesinahumansalivarygland cellline. AmJPhysiol 1996, 270 :C514-521. 10.NguyenCQ,YinH,LeeBH,CarcamoWC,ChioriniJA,PeckAB: Pathogenic effectofinterleukin-17AininductionofSjogren ssyndrome-likedisease usingadenovirus-mediatedgenetransfer. ArthritisResTher 2010, 12 :R220. 11.LeungS,LiuX,FangL,ChenX,GuoT,ZhangJ: Thecytokinemilieuinthe interplayofpathogenicTh1/Th17cellsandregulatoryTcellsin autoimmunedisease. CellMolImmunol 2010, 7 :182-189. 12.LiX,LiX,QianL,WangG,ZhangH,WangX,ChenK,ZhaiZ,LiQ,WangY, HarrisDC: Tregulatorycellsaremarkedlydiminishedindiseasedsalivary glandsofpatientswithprimarySjogren s syndrome. JRheum 2007, 34 :2438-2445. 13.McCartney-FrancisNL,MizelDE,RedmanRS,Frazier-JessenM,PanekRB, KulkarniAB,WardJM,McCarthyJB,WahlSM: AutoimmuneSjogren s-like lesionsinsalivaryglandsofTGF-beta1-deficientmiceareinhibitedby adhesion-blockingpeptides. JImmunol 1996, 157 :1306-1312. 14.PerkinsD,WangZ,DonovanC,HeH,MarkD,GuanG,WangY,WalunasT, BluestoneJ,ListmanJ,FinnPW: RegulationofCTLA-4expressionduringT cellactivation. JImmunol 1996, 156 :4154-4159. 15.TakahashiT,TagamiT,YamazakiS,UedeT,ShimizuJ,SakaguchiN,MakTW, SakaguchiS: Immunologicself-tolerancemaintainedbyCD25(+)CD4(+) regulatoryTcellsconstitutivelyexpressingcytotoxicTlymphocyteassociatedantigen4. JExpMed 2000, 192 :303-310. 16.SakaguchiS,OnoM,SetoguchiR,YagiH,HoriS,FehervariZ,ShimizuJ, TakahashiT,NomuraT: Foxp3+CD25+CD4+naturalregulatoryTcellsin dominantself-toleranceandautoimmunedisease. ImmunolRev 2006, 212 :8-27. 17.MatsumuraR,UmemiyaK,GotoT,NakazawaT,KagamiM,TomiokaH, TanabeE,SugiyamaT,SueishiM: Glandularandextraglandularexpression ofcostimulatorymoleculesinpatientswithSjogren ssyndrome. Ann RheumDis 2001, 60 :473-482. 18.Downie-DoyleS,BayatN,RischmuellerM,LesterS: InfluenceofCTLA4 haplotypesonsusceptibilityandsomeextraglandularmanifestationsin primarySjogren ssyndrome. ArthritisRheum 2006, 54 :2434-2440. 19.MorelandL,BateG,KirkpatrickP: Abatacept. NatRevDrugDiscov 2006, 5 :185-186. 20.IzawaA,SanoK,TakeharaM,InobeM,SuzukiJ,ImamuraH,TakahashiM, IkedaU,IsobeM,UedeT: Cre/loxP-mediatedCTLA4IgGgenetransfer inducesclinicallyrelevantimmunosuppressionviaon-offgene recombinationinvivo. CardiovascRes 2006, 69 :289-297. 21.CutoloM,SoldanoS,MontagnaP,SulliA,SerioloB,VillaggioB,TrioloP, ClericoP,FelliL,BrizzolaraR: CTLA4-Iginteractswithculturedsynovial macrophagesfromrheumatoidarthritispatientsanddownregulates cytokineproduction. ArthritisResTher 2009, 11 :R176. 22.KokMR,YamanoS,LoddeBM,WangJ,CouwenhovenRI,YakarS, VoutetakisA,LeroithD,SchmidtM,AfioneS,PillemerSR,TsutsuiMT, TakPP,ChioriniJA,BaumBJ: Localadeno-associatedvirus-mediated interleukin10genetransferhasdisease-modifyingeffectsinamurine modelofSjogren ssyndrome. HumGeneTher 2003, 14 :1605-1618. 23.KaludovN,BrownKE,WaltersRW,ZabnerJ,ChioriniJA: Adeno-associated virusserotype4(AAV4)andAAV5bothrequiresialicacidbindingfor hemagglutinationandefficienttransductionbutdifferinsialicacid linkagespecificity. JVirol 2001, 75 :6884-6893. 24.KanayaK,TsuchidaY,InobeM,MurakamiM,HiroseT,KonS,KawaguchiS, Wada T,YamashitaT,IshiiS,UedeT: Combinedgenetherapywith adenovirusvectorscontainingCTLA4IgandCD40Igprolongssurvivalof compositetissueallograftsinratmodel. Transplantation 2003, 75 :275-281.Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page10of11

PAGE 11

25.GrimmD,KernA,RittnerK,KleinschmidtJA: Noveltoolsforproduction andpurificationofrecombinantadenoassociatedvirusvectors. Hum GeneTher 1998, 18 :2745-2760. 26.ChaS,NagashimaH,BrownVB,PeckAB,Humphreys-BeherMG: TwoNOD Idd-associatedintervalscontributesynergisticallytothedevelopmentof autoimmuneexocrinopathy(Sjogren ssyndrome)onahealthymurine background. ArthritisRheum 2002, 46 :1390-1398. 27.KatanoH,KokMR,CotrimAP,YamanoS,SchmidtM,AfioneS,BaumBJ, ChioriniJA: EnhancedtransductionofmousesalivaryglandswithAAV5basedvectors. GeneTher 2006, 13 :594-601. 28.YinH,VisticaBP,ChanCC,StromingerJL,GeryI: Inhibitionofexperimental autoimmuneuveitisbyaminoacidcopolymers. JNeuroimmunol 2009, 215 :43-48. 29.NguyenCQ,SharmaA,LeeBH,SheJX,McIndoeRA,PeckAB: Differential geneexpressioninthesalivaryglandduringdevelopmentandonsetof xerostomiainSjogren ssyndrome-likediseaseoftheC57BL/6.NODAec1Aec2mouse. ArthritisResTher 2009, 11 :R56. 30.WhittinghamS,NaselliG,McNeilageLJ,CoppelRL,SturgessAD: Serological diagnosisofprimarySjogren ssyndromebymeansofhuman recombinantLa(SS-B)asnuclearantigen. Lancet 1987, 2 :1-3. 31.GreenspanJS,DanielsTE,TalalN,SylvesterRA: Thehistopathologyof Sjogren ssyndromeinlabialsalivaryglandbiopsies. OralSurgOralMed OralPathol 1974, 37 :217-229. 32.CotrimAP,BaumBJ: Genetherapy:somehistory,applications,problems, andprospects. ToxicolPathol 2008, 36 :97-103. 33.VoutetakisA,KokMR,ZhengC,BossisI,WangJ,CotrimAP,MarracinoN, GoldsmithCM,ChioriniJA,LohYP,NiemanLK,BaumBJ: Reengineered salivaryglandsarestableendogenousbioreactorsforsystemicgene therapeutics. ProcNatlAcadSciUSA 2004, 101 :3053-3058. 34.TsunawakiS,NakamuraS,OhyamaY,SasakiM,Ikebe-HirokiA,HirakiA, KadenaT,KawamuraE,KumamaruW,ShinoharaM,ShirasunaK: Possible functionofsalivaryglandepithelialcellsasnonprofessionalantigenpresentingcellsinthedevelopmentofSjogren ssyndrome. JRheumatol 2002, 29 :1884-1896. 35.HoweKL,ReardonC,WangA,NazliA,McKayDM: Transforminggrowth factor-betaregulationofepithelialtightjunctionproteinsenhances barrierfunctionandblocksenterohemorrhagicEscherichiacoliO157:H7inducedincreasedpermeability. AmJPathol 2005, 167 :1587-1597. 36.SamuniY,BaumBJ: Genedeliveryinsalivaryglands:fromthebenchto theclinic. BiochimBiophysActa 2011, 1812 :1515-1521.doi:10.1186/ar3753 Citethisarticleas: Yin etal .: LocaldeliveryofAAV2-CTLA4IgG decreasessialadenitisandimprovesglandfunctionintheC57BL/6. NODAec1Aec2 mousemodelofSjgren ssyndrome. ArthritisResearch& Therapy 2012 14 :R40. Submit your next manuscript to BioMed Central and take full advantage of: Convenient online submission Thorough peer review No space constraints or color gure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit Yin etal ArthritisResearch&Therapy 2012, 14 :R40 http://arthritis-research.com/content/14/1/R40 Page11of11


xml version 1.0 encoding utf-8 standalone no
mets ID sort-mets_mets OBJID sword-mets LABEL DSpace SWORD Item PROFILE METS SIP Profile xmlns http:www.loc.govMETS
xmlns:xlink http:www.w3.org1999xlink xmlns:xsi http:www.w3.org2001XMLSchema-instance
xsi:schemaLocation http:www.loc.govstandardsmetsmets.xsd
metsHdr CREATEDATE 2012-03-13T16:19:30
agent ROLE CUSTODIAN TYPE ORGANIZATION
name BioMed Central
dmdSec sword-mets-dmd-1 GROUPID sword-mets-dmd-1_group-1
mdWrap SWAP Metadata MDTYPE OTHER OTHERMDTYPE EPDCX MIMETYPE textxml
xmlData
epdcx:descriptionSet xmlns:epdcx http:purl.orgeprintepdcx2006-11-16 xmlns:MIOJAVI
http:purl.orgeprintepdcxxsd2006-11-16epdcx.xsd
epdcx:description epdcx:resourceId sword-mets-epdcx-1
epdcx:statement epdcx:propertyURI http:purl.orgdcelements1.1type epdcx:valueURI http:purl.orgeprintentityTypeScholarlyWork
http:purl.orgdcelements1.1title
epdcx:valueString Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjogren's syndrome
http:purl.orgdctermsabstract
Abstract
Introduction
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key negative costimulatory molecule that displays a wide range of anti-inflammatory properties and is currently approved to treat rheumatoid arthritis as a recombinant fusion protein (CTLA4IgG). To better understand the role of CTLA4IgG in primary Sjögren's syndrome (pSS), we generated a recombinant adeno-associated virus vector serotype 2 (AAV2) expressing a chimera of mouse CTLA-4 fused with a human immunoglobulin (AAV2-CTLA4IgG) and observed the effect of this molecule in C57BL/6.NOD-Aec1Aec2 mice, an animal model of pSS.
Methods
A recombinant adeno-associated virus-2 (AAV-2) vector was constructed encoding a CTLA4IgG fusion protein. The AAV2-CTLA4IgG vector and an AAV2 control vector encoding beta galactosidase (LacZ) were administered by retrograde cannulation of the submandibular glands of C57BL/6.NOD-Aec1Aec2 mice. Protein expression was measured by ELISA and salivary glands were assessed for inflammation and activity.
Results
Recombinant CTLA4IgG blocked B7 expression on macrophages in vitro. In vivo, localized expression of CTLA4IgG in the salivary glands of C57BL/6.NOD-Aec1Aec2 mice inhibited the loss of salivary gland activity and decreased T and B cell infiltration as well as dendritic cells and macrophages in the glands compared with control mice. In addition a decrease in several proinflammatory cytokines and an increase in transforming growth factor beta-1 (TGF-β1) expression were also observed.
Conclusions
These data suggest expression of CTLA4IgG in the salivary gland can decrease the inflammation and improve the xerostomia reported in these mice.
http:purl.orgdcelements1.1creator
Yin, Hongen
Nguyen, Cuong Q
Samuni, Yuval
Uede, Toshimitsu
Peck, Ammon B
Chiorini, John A
http:purl.orgeprinttermsisExpressedAs epdcx:valueRef sword-mets-expr-1
http:purl.orgeprintentityTypeExpression
http:purl.orgdcelements1.1language epdcx:vesURI http:purl.orgdctermsRFC3066
en
http:purl.orgeprinttermsType
http:purl.orgeprinttypeJournalArticle
http:purl.orgdctermsavailable
epdcx:sesURI http:purl.orgdctermsW3CDTF 2012-02-27
http:purl.orgdcelements1.1publisher
BioMed Central Ltd
http:purl.orgeprinttermsstatus http:purl.orgeprinttermsStatus
http:purl.orgeprintstatusPeerReviewed
http:purl.orgeprinttermscopyrightHolder
Yin et al.; licensee BioMed Central Ltd.
http:purl.orgdctermslicense
http://creativecommons.org/licenses/by/2.0
http:purl.orgdctermsaccessRights http:purl.orgeprinttermsAccessRights
http:purl.orgeprintaccessRightsOpenAccess
http:purl.orgeprinttermsbibliographicCitation
Arthritis Research & Therapy. 2012 Feb 27;14(1):R40
http:purl.orgdcelements1.1identifier
http:purl.orgdctermsURI http://dx.doi.org/10.1186/ar3753
fileSec
fileGrp sword-mets-fgrp-1 USE CONTENT
file sword-mets-fgid-0 sword-mets-file-1
FLocat LOCTYPE URL xlink:href ar3753.xml
sword-mets-fgid-1 sword-mets-file-2 applicationpdf
ar3753.pdf
structMap sword-mets-struct-1 structure LOGICAL
div sword-mets-div-1 DMDID Object
sword-mets-div-2 File
fptr FILEID
sword-mets-div-3


!DOCTYPE art SYSTEM 'http:www.biomedcentral.comxmlarticle.dtd'
ui ar3753
ji 1478-6354
fm
dochead Research article
bibl
title p Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-it Aec1Aec2 mouse model of Sjögren's syndrome
aug
au id A1 ce yes snm Yinfnm Hongeninsr iid I1 email yinho@mail.nih.gov
A2 Nguyenmi QCuongI2 nguyen@pathology.ufl.edu
A3 SamuniYuvalyuvalsamuni@gmail.com
A4 UedeToshimitsuI3 toshi@igm.hokudai.ac.jp
A5 PeckBAmmonpeck@pathology.ufl.edu
A6 ca ChioriniAJohnjchiorini@dir.nidcr.nih.gov
insg
ins Molecular Physiology and Therapeutics Branch, National Institute of Dental and Cranial Research, National Institutes of Health, 10 Center Drive, MSC1190, Bethesda, MD 20892, USA
Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida
Section of Immunopathogenesis, Institute of Immunological Science, Hokkaido University, Sapporo, Hokkaido 060, Japan
source Arthritis Research & Therapy
issn 1478-6354
pubdate 2012
volume 14
issue 1
fpage R40
url http://arthritis-research.com/content/14/1/R40
xrefbib pubidlist pubid idtype doi 10.1186/ar3753pmpid 22369699
history rec date day 10month 6year 2011revrec 2122011acc 2722012pub 2722012
cpyrt 2012collab Chiorini et al.; licensee BioMed Central Ltd.note This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
kwdg kwd Sjögren's Syndromesalivary gland dysfunctionadeno-associated virus (AAV)CTLA4IgG fusion proteinprevention
abs
sec st Abstract
Introduction
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key negative costimulatory molecule that displays a wide range of anti-inflammatory properties and is currently approved to treat rheumatoid arthritis as a recombinant fusion protein (CTLA4IgG). To better understand the role of CTLA4IgG in primary Sjögren's syndrome (pSS), we generated a recombinant adeno-associated virus vector serotype 2 (AAV2) expressing a chimera of mouse CTLA-4 fused with a human immunoglobulin (AAV2-CTLA4IgG) and observed the effect of this molecule in C57BL/6.NOD-Aec1Aec2 mice, an animal model of pSS.
Methods
A recombinant adeno-associated virus-2 (AAV-2) vector was constructed encoding a CTLA4IgG fusion protein. The AAV2-CTLA4IgG vector and an AAV2 control vector encoding beta galactosidase (LacZ) were administered by retrograde cannulation of the submandibular glands of C57BL/6.NOD-Aec1Aec2 mice. Protein expression was measured by ELISA and salivary glands were assessed for inflammation and activity.
Results
Recombinant CTLA4IgG blocked B7 expression on macrophages in vitro. In vivo, localized expression of CTLA4IgG in the salivary glands of C57BL/6.NOD-Aec1Aec2 mice inhibited the loss of salivary gland activity and decreased T and B cell infiltration as well as dendritic cells and macrophages in the glands compared with control mice. In addition a decrease in several proinflammatory cytokines and an increase in transforming growth factor beta-1 (TGF-β1) expression were also observed.
Conclusions
These data suggest expression of CTLA4IgG in the salivary gland can decrease the inflammation and improve the xerostomia reported in these mice.
bdy
Introduction
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disorder that results in impaired exocrine gland function. Xerostomia (dry mouth) and xerophthalmia (conjunctivitis sicca, dry eyes) are hallmarks of Sjögren's syndrome abbrgrp abbr bid B1 1. The mechanism associated with Sjögren's syndrome is unclear however, immunologically-activated or apoptotic glandular epithelial cells may present novel autoantigens in predisposed individuals driving autoimmune-mediated tissue injury B2 2B3 3. Immune activation is typically presented as focal, mononuclear (T, B, dentritic, and macrophage) cell infiltrates, proximal to the ductal epithelial cells and forms sialadenitis 2. Lymphocytic infiltrations in the salivary gland (SG) and lachrymal glands (LG) consist of 60% to 70% CD4+ T-lymphocytes, and a substantial numbers of B cells, dendritic cells (DCs), plasma, and macrophage (Mф) cells 2B4 4B5 5. Abnormal activation of proinflammatory Th1 B6 6B7 7, and Th17 B8 8 cells and cytokines such as interferon-γ (IFN-γ), interleukin-12 (IL-12), IL-17 were reported in animal models of pSS and patient samples 78B9 9B10 10B11 11. In addition, a dramatic drop in T regulatory cells (Treg) and decreased expression of TGF-β1 in SG infiltrates was also reported in pSS patients B12 12. Furthermore, TGF-β1 deficient mice develop a Sjögren's syndrome like autoimmune disease B13 13.
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an important immune regulatory protein and displays a wide range of activities associated with immune tolerance. By competing with CD28 to bind B7-1/2 (CD80/CD86), CTLA4 blocks the activation of T cells, thus maintaining immune homeostasis B14 14. CTLA-4 is constitutively expressed on Treg cells and also binds to B7 on antigen-presenting cells (APCs) to inhibit activation of effector T cells B15 15B16 16. Recently it is noted that epithelial cells in the minor SGs of pSS patients express costimulatory molecules B7.1 (CD80) and B7.2 (CD86) B17 17. Correspondingly, different haplotypes of CTLA-4 were found to be associated with increased susceptibility to pSS B18 18.
Currently, a recombinant fusion protein of CTLA4-immunoglobulin (CTLA4-Ig, Abatacept, Orencia) is licensed in the United States for the treatment of rheumatoid arthritis 5. Abatacept, which contains the CTLA-4 high-affinity binding site for B7 blocks B7:CD28 costimulatory signaling pathway and is reported to shut down activation of proinflammatory T cells B19 19 as well as B cells, DCs, and Mф B20 20B21 21.
In order to study the affect of CTLA4 blockade on the sialadenitis and xerostomia associated with Sjögren's syndrome, CTLA4IgG was locally expressed in the salivary glands of C57BL/6.NOD-Aec1Aec2 mice, which develop a Sjögren's syndrome-like disease. Our findings of both functional and immunological improvement in the mice warrant further investigation of CTLA4 mediated immunomodulation as a therapeutic pathway for treatment of pSS patients.
Materials and methods
Cell lines
HEK-293T cells were grown in Dulbecco's modified Eagle's medium (DMEM). Medium was supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Rockville, MD, USA), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml; Biofluids, Rockville, MD, USA) as previously described B22 22.
Construction and testing of AAV2-CTLA4IgG
We previously reported construction of AAV2-LacZ B23 23. In this study we used the extracellular domain of mouse Cytotoxic T-lymphocyte antigen 4 (CTLA4) coupled to human Immunoglobulin G (IgG) Cγ1 (CTLA4IgG), kindly provided by Dr Toshimitsu Uede (Institute of Immunological Science, Hokkaido University, Hokkaido, Japan) B24 24. This gene was cloned into the recombinant adeno-associated virus (AAV) plasmid containing a cytomegalovirus (CMV) promoter and the inverted terminal repeat (ITRs) sequences for AAV serotype 2 (AAV2). The plasmid (AAV2-CTLA4IgG) was transfected into HEK-293T cells and expression of the protein in the media was determined by western blotting after electrophoresis in reducing conditions using anti-mCTLA4 Ab (R&D systems, Minneapolis, MN, USA).
Competitive inhibition of B7 association by CTLA4IgG in vitro
Mouse macrophages (CRL-2751, ATCC) were grown in DMEM with 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose (Biofluids, Rockville, MD, USA), 10% fetal bovine serum, and 20% LADMAC conditioned media (produced from the LADMAC cell line (CRL-2420) at 37°C in a humidified, 5% COsub 2 atmosphere, incubator. 1 × 10sup 5 cells/well were placed in round bottom 96-well plates and spun down at 1500 rpm in a bench top centrifuge at 4°C. The cells were then washed twice with PBS (pH 7.4, 0.05% Tween 20) and incubated for 1 h at 37°C with either medium from control HEK-293T cells or from HEK-293T cells transfected with AAV2-CTLA4IgG. Following additional washes, the cells were incubated in the dark with 0.5 to 1 μg/ml of Armenian hamster IgG FITC-conjugated anti B7-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in blocking solution (PBS, pH 7.4, 0.5% BSA) at 4°C for 40 min. The cells were then washed and analyzed by flow cytometry assay.
Vector production
To generate AAV2 vectors, we used the adenoviral helper packaging plasmid pDG. Fifteen-cm plates of approximately 40% confluent HEK-293 T cells were co-transfected with either AAV-LacZ or AAV-CTLA4IgG according to standardized methods B25 25. Clarified cell lysates were adjusted to a refractive index of 1.372 by addition of CsCl, and centrifuged at 38,000 rpm for 65 h at 20°C. Equilibrium density gradients were fractionated and fractions with a refractive index of 1.369 to 1.375 were collected. The particle titer was determined by Q-PCR and the vector was stored at -80°C. On the day of vector administration to C57BL/6.NOD-Aec1Aec2 mice, the vector was dialyzed for 3 h against saline.
Animals
Three female and ten male C57BL/6.NOD-Aec1Aec2 mice, aged six weeks, were bred and maintained at the animal facility of the Department of Pathology, University of Florida, as described previously B26 26. Baseline saliva and tear flow was collected from mice when they were six weeks old. Gene therapy studies, as described herein, were approved by the University of Florida's IACUC and IBC.
AAV2 vector administration
Mice were randomly grouped and vectors were delivered into the submandibular glands by retrograde instillation as previously described 22 (AAV2-LaZ: 1 female, 5 males and AAV2-CTLA4IgG: 2 females, 5 males). As previously reported, the vector was well tolerated with no vector related inflammation 22B27 27. Briefly, eight-week-old mice were mildly anesthesized with ketamine (100 mg/ml, 1 ml/kg body weight; Fort Dodge Animal Health, Fort Dodge, IA, USA) and xylazine (20 mg/ml, 0.7 ml/kg body weight; Phoenix Scientific, St Joseph, MO, USA) solution given by intramuscular injection (IM). Ten minutes after IM injection of atropine (0.5 mg/kg BW; Sigma, St Louis, MO, USA), mice were administered 50 μl AAV2 vector into both submandibular glands by retrograde ductal instillation (1 × 1010 particles/gland) using a thin cannula.
Detection of CTLA4IgG expression in salivary glands and serum from C57BL/6.NOD-Aec1Aec2 mice
To confirm the stable expression of CTLA4IgG in vivo after local delivery in the SGs from C57BL/6.NOD-Aec1Aec2 mice, homogenates of SGs were prepared as described previously 7. Total protein in the supernatant was determined with BCA™ protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Blood was collected by cardiac puncture at the time of sacrificing and collected in microcentrifuge tubes. Serum was separated by centrifugation for 20 min at 2000 g and stored at -80°C.
CTLA4IgG was detected by sandwich ELISA. A 96-well plate (Nunc, Rochester, NY, USA) was incubated overnight (O/N) with 0.4 μg/ml capture antibody, goat anti-mouse CTLA-4 Ab (R&D, Minneapolis, MN, USA) in carbonate/bicarbonate buffer (pH9.5). The next day, wells were blocked and incubated with 100 μL of appropriately diluted standard control (0.0850 μg/ml rCTLA4, R&D, Minneapolis, MN, USA) or serum, undiluted SG homogenates for 2 h according to the product instructions. Following three washings, the wells were incubated with a 1:5,000 dilution of peroxidase conjugated affinity purified goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at RT. Substrate reaction was developed following the manufacturer's protocol and the plate were read at OD 450 nm using a Microplate reader model 680 (Bio-Rad Laboratories, Hercules, CA, USA) 7.
Measurement of salivary and tear flow rates
Pilocarpine stimulated saliva flow rate (SFR) and tear flow rate (TFR) collection was performed as described previously 8 at the indicated time points. Briefly, individual non-anesthetized mice were weighed and given an i.p. injection of 100 μl of PBS containing a mixture of isoproterenol (0.02 mg/ml) and pilocarpine (0.05 mg/ml). Saliva was collected from the oral cavity of individual mice for 10 min. At week 30, tear volumes from individual animal were measured after i.p. injection of pilocarpine (4.5 mg/g [BW]) for 20 s and determined using a phenol red thread (Zone-Quick, FCI Ophthalmics, Pembrooke, MA, USA), a modified version of the Schirmer test as described 8. SFR and TFR were then calculated per gram body weight.
Determination of autoantibodies
At the end of the study, serum was collected from 30-week-old C57BL/6.NOD-Aec1Aec2 mice. An ELISA was developed as described previously 7 to detect autoantibodies against SSA/Ro [multiple antigenic peptide (MAP)-Ro273] (University of Oklahoma Health Sciences Molecular Biology core Facility, Oklahoma City, OK, USA). Autoantibodies against SSB/La (total Ig) were measured by a commercially available ELISA kit (Alpha Diagnostic International, San Antonio, TX, USA) according to the manufacturer's protocol.
Histological assessment of salivary glands
Following euthanasia, whole SGs were surgically removed from each mouse and placed in 10% phosphate-buffered formalin for 24 h for hematoxylin and eosin (H&E) staining as described previously 10. Stained sections were observed under a microscope for glandular structure and leukocyte infiltration. Unstained sections were used for immunofluorescence and immunochemistry staining (below).
Immunofluorescence staining for CD3+T cells and B220+B cells
Immunofluorescence staining for T and B cells for the infiltrations in the SGs was done as previously described 8. Briefly histological sections of salivary glands were incubated with rat anti-mouse B220 (BD Pharmingen, San Jose, CA, USA) and goat anti-mouse CD3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation with Texas Red-conjugated rabbit anti-rat IgG (Biomeda, Foster City, CA, USA) and FITC-conjugated rabbit anti-goat IgG (Sigma-Aldrich, St. Louis, MO, USA). The slides were mounted with DAPI-mounting medium (Vector Laboratories, Burlingame, CA, USA). Sections were observed at 200× magnification using a Zeiss Axiovert 200M microscope, and images were obtained with AxioVs40 software (Ver. 4.7.1.0, Zeiss) (Carl Zeiss, Thornwood). The number of lymphocytic foci (LF) in each section was blindly enumerated by three individual investigators. The number of B and T cells, and total number of nuclei in each LF were determined using Mayachitra image software (Mayachitra, Inc., Santa Barbara, CA, USA).
Immunohistochemical staining for CD11c and F4/80 in salivary glands
Paraffin-embedded SGs were deparaffinized by immersion in xylene, followed by antigen retrieval with 10 mM citrate buffer, pH 6.0. Tissue sections were then incubated overnight at 4°C with anti-CD11c or anti-F4/80 antibody (Santa Cruz Biotechnology Santa Cruz, CA, USA). Total rabbit IgG was used as an isotype control. The slides were incubated with biotinylated goat anti-rabbit IgG secondary antibody followed by horseradish peroxidase-conjugated strepavidin incubation using the Vectastain ABC kit. The staining was developed by using diaminobenzidine substrate (Vector Laboratories, Burlingame, CA, USA), and counterstaining was performed with hematoxylin. Sections were photographed at 200× magnification using a Zeiss Axiovert 200M microscope, and images were obtained with AxioVs40 software (Ver. 4.7.1.0, Zeiss) (Carl Zeiss, Thornwood). The number of CD11c or F4/80-positive cells was counted by three different examiners and the mean of three counting were determined.
Detection of cytokines from immune cell cultures and SG homogenates
Cytokines from spleen cell and draining lymph nodes (DLN) cell culture, serum, and homogenates of SGs were detected as described previously B28 28. Briefly cells from spleen and submadibular salivary gland (SMGs) associated DLNs obtained from treated mice were isolated respectively and samples from mice in each group were pooled and cultured in 24-well plates at 5 × 106 cells/ml RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA), containing HL-1 serum replacement (Cambrex Bioscience, Walkersville, MD, USA), with or without 1 μg/ml Concanavalin A (ConA, Sigma-Aldrich, St Louis, MO, USA). Supernatants were collected after 48 h incubation. Serum and SMG homogenates were prepared as described previously 728 and three samples from representative mice in each group were used for detection.
Murine interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), IL-12 p70, interferon-γ (IFN-γ), IL-18, IL-17, IL-23, transforming growth factor-β1 (TGF-β1), mast cell proteinase-1 (MCP-1), and macrophage inflammatory proteins-1 (MIP-1) were measured using a multiplex sandwich-ELISA assay (Aushon Biosystem Billerica, MA, USA). Duplicates for each sample were tested in three dilutions and the mean values of the duplicates from the optimal dilution were reported 28.
Statistical analysis
Mann-Whitney U test was used to analyze differences of cytokine production in serum. Unpaired student t-test was used to analyze differences between two experimental groups in other assays. All analyses were performed with GraphPad Prism statistical software (GraphPad Software Inc. version 4.02, La Jolla, CA, USA) using a P value ≤0.05 as statistically significant.
Results
Detection of CTLA4IgG and binding to B7 in vitro
Prior to analyzing stable expression of CTLA4IgG from AAV2-CTLA4IgG in the SGs of C57BL/6.NOD-Aec1Aec2 mice, we confirmed both the expression and the biological activity of the fusion protein by western blot, and by blocking the B7:CD28 pathway in vitro, respectively.
Fusion of the Cγ1 domain of IgG to the binding domain of CTLA4 resulted in a chimeric protein of approximately 62 kDa. Secretion was confirmed by western blot of the cell culture media from transfected cells (Figure figr fid F1 1A).
fig Figure 1caption In vitro expression and activity of CTLA4IgGtext
b In vitro expression and activity of CTLA4IgG. (A) In vitro expression of CTLA4IgG was detected by western blot of media from AAV2-CTLA4 transfected cells (lane 3). As a control, purified recombinant mouse CTLA4/Fc was also run on the gel (lane 2). (B) Biological activity of CTLA4IgG, based on its ability to bind and block B7.1, was determined by incubating with either medium from naïve HEK-293T cells (column 1) or from cells transfected with AAV2CTLA4 (column 2). Unbound B7.1 was then tested by flow cytometry using an antibody to B7.1. Data shown is mean from three independent experiments (asterisk, P = 0.0400). Unpaired student-t test was used in this analysis.
graphic file ar3753-1
Macrophages, like dendritic cells, are one of the antigen presenting cells (APCs) that express the costimulatory molecule B7. To test the ability of the recombinant CTLA4IgG to bind and block B7 detection, supernatant from CTLA4IgG expressing cells was preincubated with macrophages and then B7 quantified by flow cytometry assay. Compared to macrophages incubated without CTLA4IgG, unbound and detectable B7 expression on the macrophages incubated with CTLA4IgG was decreased, suggesting binding between B7 and CTLA4IgG.
In vivo expression of CTLA4IgG following cannulation with AAV2-CTLA4IgG in C57BL/6.NOD-Aec1Aec2 mice
Salivary gland infiltrating lymphocytes in C57BL/6.NOD-Aec1Aec2 are first detected between 8 and 12 weeks of age. However, microarray analysis indicates that adhesion molecules as well as genes associated with macrophages and dendritic cells are upregulation as early as 8 weeks of age. Prior to 8 weeks SGs are not considered fully mature. Thus, we chose to cannulate the glands at 8 weeks which would be considered an our early stage of disease B29 29. As previously reported, cannulation of these mice with AAV vectors was well tolerated and no vector related inflammation was observed 2227. To confirm the stable expression of CTLA4IgG in vivo after local delivery of AAV2-CTLA4IgG to the SGs of C57BL/6.NOD-Aec1Aec2 mice, SG homogenates and serum were obtained at the end of the study (30 weeks) and pooled according to each group. Using a sandwich-ELISA to detect the recombinant chimeric protein (mouse CTLA4 and human IgG), mice that received AAV2-CTLA4IgG had much higher levels of CTLA4IgG (44.5 ± 0.76 pg/ml in SG and 7.48 ± 0.70 pg/ml in serum, mean ± SD) in both their SG and serum compared with mice that received vector expressing LacZ (0.39 ± 0.02 pg/ml in SG and 0.62 ± 0.01 pg/ml in serum) (P = 0.0003 and P = 0.0102, respectively, in SG and serum) (Figure F2 2). In agreement with the local delivery of vector, the level of expression in the SG homogenates was elevated compared with serum in the AAV2- CTLA4IgG-treated mice.
Figure 2In vivo expression of CTLA4IgG in salivary glands from C57BL/6.NOD-Aec1Aec2 mice
In vivo expression of CTLA4IgG in salivary glands from C57BL/6.NOD-Aec1Aec2 mice. A sandwich ELISA was developed to detect expression of mouse CTLA4 and human IgG (CTLA4IgG) chimeras in homogenates of submandibular salivary glands (A) and serum (B) (Materials & Methods). Data show the mean ± SEM from each group. Mice cannnulated with AAV2-CTLA4IgG (n = 6, pooled into two samples/group) had significant levels of CTLA4IgG protein in the salivary glands compared with mice that received AAV2-LacZ (n = 7, pooled into two samples/group), (two asterisks, P = 0.0003) and serum (asterisk, P = 0.0102) Unpaired student-t test was used in this analysis.
ar3753-2
Local expression of AAV2-CTLA4IgG prevents the age-dependent loss of salivary gland activity in C57BL/6.NOD-Aec1Aec2 mice
To better understand the effect of CTLA4IgG on SG function, stimulated saliva flow was measured in both treated and control mice over time. In agreement with previous studies 26, mice treated with the control LacZ expressing vector showed a significant decrease of saliva flow by 16 weeks (4.25 ± 0.64 μL/g 10 min), compared with the baseline flow at 6 weeks (6.10 ± 0.30 μL/g 10 min), which continued to decline over time 8. Mice that received AAV2CTLA4IgG vector initially also showed some decrease in saliva flow at 16 weeks (5.13 ± 1.22 μL/g 10 min), but it was not statistically significant compared with the 6-week baseline (P = 0.2057). However, by 22 weeks the saliva flow from the CTLA4IgG mice had recovered to near baseline values (6.13 ± 0.92 μL/g 10 min), which was sustained for the remainder of the study, and was statistically different compared with the AAV2-LacZ-treated group at 30 weeks (P = 0.0222). These data suggest that expression of CTLA4IgG in the SGs of C57BL/6.NOD-Aec1Aec2 mice can inhibit the loss of SG function (Figure F3 3A).
Figure 3Stimulated saliva and tear flow in treated C57BL/6.NOD-Aec1Aec2 mice
Stimulated saliva and tear flow in treated C57BL/6.NOD-Aec1Aec2 mice. Saliva and tear flow were collected as described in the Materials & Methods section. The data shown represent the mean ± SEM flow per group (n = 6 in AAV2-LacZ group and n = 7 in AAV2-CTLA4IgG group). Unpaired student t-test was used in this analysis. (A) Mice treated with vector expressing CTLA4IgG showed protection from loss of gland activity. Saliva was collected over a 10-min period after stimulation with a 100 μl of PBS containing a mixture of isoproterenol (0.02 mg/ml) and pilocarpine (0.05 mg/ml) and tear flow were collected over a 20-s period after injection of pilocarpine (4.5mg/kg body weight). AAV2-LacZ mice showed decreased saliva on weeks 16, 22, 26, and 30 (asterisk, P = 0.0428, 0.0217, 0.0292, and 0.0128, respectively), compared with the baseline saliva collection on week 6 (n = 9, 5.933 ± 0.2969). AAV2-CTLA4IgG-treated mice had a slight decrease of saliva but this was not significant at 16 weeks (P = 0.2057). Saliva flow of CTLA4IgG-treated mice increased to baseline level by 22 weeks (6.13 ± 0.92 μL/g 10 min). CTLA4IgG-treated mice had increased saliva flow compared with LacZ-treated mice by 30 weeks (P = 0.0232). (B) Delivery of AAV2-CTLA4IgG resulted in an increase in tear flow (mean ± SEM) by 30 weeks compared with control mice, but this was not significant (P = 0.1316).
ar3753-3
Salivary gland transduction with AAV2 CTLA4IgG had only minimal affect on lachrymal gland dysfunction in C57BL/6.NOD-Aec1Aec2 mice
Previous research has suggested that following cannulation of the SG, greater than 90% of the AAV2 vector remains in the gland 27. Similarly higher levels of the expression can also be detected locally in the gland homogenates compared with circulating levels. In order to test if the circulating levels of CTLA4IgG were sufficient to have an effect on other secretory epithelia such as the loss of lachrymal gland function in the C57BL/6.NOD-Aec1Aec2 mice, we measured stimulated tear flow at the end of the study. CTLA4IgG-treated mice had an overall increase in tear flow compared with the LacZ-expressing group, but was not significantly different (P = 0.1316) (Figure 3B).
CTLA4IgG expression does not change autoantibody levels in C57BL/6.NOD-Aec1Aec2 mice
To observe the effect of CTLA4IgG on the regulation of systemic B cell activation, we measured anti-Ro (SSA) and anti-La (SSB) autoantibodies, which are highly correlated with pSS B30 30. Minimal changes in anti-Ro and anti-La titer were detected in the CLTA4IgG-treated mice compared with the AAV2-LacZ-treated mice (Figures F4 4A and 4B).
Figure 4Serum anti-nuclear antibody productions in C57BL/6.NOD-Aec1Aec2 mice
Serum anti-nuclear antibody productions in C57BL/6.NOD-Aec1Aec2 mice. Serum samples were analyzed for anti-Ro (SSA) (A) and anti-La (SSB) (B) antibody expression in serum from AAV2-LacZ (n = 6) and AAV2-CTLA4IgG (n = 7) treated mice by ELISA. The data shown represent the mean ± SEM in OD or U/ml from duplicate tests of pooled samples from each group. Unpaired student's t-test was used for statistical analysis. No statistically significant difference was detected (P = 0.9586 and 0.4158, respectively).
ar3753-4
Salivary gland transduction with AAV2 CTLA4IgG can decrease infiltrating T and B cells, DCs, and Mф
To determine the effect of CTLA4IgG on lymphocyte foci (LF) in the SGs, we detected the number of LF as well as the number of T and B cells within the gland by immunofluorescence staining of CD3 and B220, respectively (Figures F5 5A, B, C, and 5D). The number of LF were decreased in the SGs of CTLA4IgG mice (0.71 LF/per gland) compared with control LacZ mice (2.16 LFs/per gland). Furthermore, the number of T and B cells present in the LF also decreased. Although the decrease in T cells was significant, the change in B cells was not statistically significant compared with control LacZ-treated mice (P = 0.0464 and P = 0.3024 for analysis of T and B cells, respectively) (Figures 5C, D, E and 5F).
Figure 5Histological examination of salivary glands
Histological examination of salivary glands. Salivary gland histology was examined at the end of the study (30 weeks of age). CD3+T and B220+B cell immunofluorescence staining, as well as CD11c and F4/80 immunochemistry staining for dendritic and macrophages cells respectively were done as described in Materials and Methods. Panels show representative immuno-fluorescence staining of salivary of B and T cells in SGs from mice cannulated with AAV2-LacZ (n = 6) or AAV2-CTLA4IgG vector (n = 7) (A, B, and C) (Blue arrows) and enumeration (mean ± SEM) (D) of B and T cells in SGs from LacZ- and CTLA4IgG- treated mice; immunohistochemical staining and enumeration (mean ± SEM) of CD11c+ DCs (E, F, G, and H) and F4/80+ macrophages (I, J, K, and L) (Black arrows) in SGs from LacZ- and CTLA4IgG-treated C57BL/6.NOD-Aec1Aec2 mice. A statistical decrease in the enumeration of both T cells was shown in the SGs from CTLA4 overexpressing mice compared to the LacZ-treated (P = 0.0464). No statistical significance but a trend was shown (P = 0.3024) for decrease trend of B cells. Significant down-regulation of both CD11c+ dendritic cells and F4/80+macrophages was seen in the SGs from CTLA4IgG-treated mice compared with control (two asterisks, P ≤0.01). Unpaired student-t test was used in the analysis.
ar3753-5
An increase in DCs and macrophages has also been reported in the SGs of pSS patients B31 31. The number of DCs and Mф cells (detected by staining for CD11c+ DCs and F4/80+, respectively) was significantly decreased in the CTLA4IgG-treated group compared with the LacZ control group (DCs: 13.33 ± 2.78/gland in LacZ group vs. 2.14 ± 0.70/per gland in CTLA4IgG mice, P ≤0.01. Mф: 14.89 ± 0.11/gland in LacZ group vs. 3.84 ± 2.31/per gland in CTLA4IgG mice, P ≤0.0001) (Figure 5E, F, G, H, I, J, K and 5L). These data indicate that local expression of CTLA4IgG can inhibit T-cell accumulation in the SG, as well as DCs and Mф.
CTLA4IgG expression decreased proinflammtory cytokines and increased TGF-β1 in salivary gland associated lymph nodes
To investigate cytokine production after CTLA4IgG expression, we measured the levels of cytokine associated with different populations of T cells or macrophages in both spleen and serum as well as locally in the SG and associated draining lymph nodes (DLN).
In SG homogenates, only a decrease in IL-6 was observed in the AAV2-CTLA4IgG-treated mice (median = 169.60 pg/ml) compared with AAV2-LacZ controls (median = 86.51 pg/ml), which was not statistically significant (P = 0.9062, data not shown). Interestingly, TGF-β1 production increased in the CTLA4IgG group compared with control LacZ-treated mice, however the increase was not statistically significant (median = 1208.70 pg/ml vs. median = 804.53 pg/ml, respectively) (P = 0.093, data not shown). In the pooled cell culture media of the DLN cells associated with the SG, a general down-regulation in proinflammatory cytokine was observed in the CTLA-4IgG-treated mice compared with control LacZ mice. Th1 cytokines (IL-12, IFN-γ, and IL-18) and Th17 cytokine (IL-23) were all down-regulated. Again, TGF-β1 was strikingly up-regulated. In addition, non-specific proinflammatory cytokines, IL-6 and TNF-α, as well as chemokines MCP-1 and MIP-1α, which are mainly released from macrophages, were decreased (Table tblr tid T1 1). Little change was detected in Th2 cytokines such as IL-4, IL-5, and IL-13 after local expression of CTLA4IgG (data not shown). These changes suggest that CTLA4IgG expression can reduce proinflammatory cytokines released by Th1, Th17 cells, DCs, and macrophages, while stimulating production of anti-inflammatory cytokines such as TGF-β1. This further supports the finding of reduced inflammation with CTLA4IgG treatment.
tbl Table 1Cytokine production local and systemic immune system in vector treated mice (pg/ml)tblbdy cols 8
r
c
cspan 2 left
DLN cells
Spleen cells
Serum
6
hr
LacZ
CTLA4IgG
LacZ
CTLA4IgG
LacZ
CTLA4IgG
Th1-
IL-12p70
12
0.00↓
4.6
0.20
88.5 ± 15.8
88.5 ± 15.8
IFN-γ
3.8
0.00↓
122
115.0
872.6 ± 1,276.8
457.2 ± 371.8↓
IL-18
11
0.00↓
16
0.00↓
694 ± 562
394.10↓
Th17-
IL-17
N/A
N/A
2.1
0.00↓
2.8 ± 3.3
N/A↓
IL-23
14
N/A↓
78.2
36.10↓
335.6 ± 365.7
101.99↓
Treg- or SG epithelial cells
TGF-β1
N/A
41,410↑
2,084
1,384
1,501,176 ± 277,249
1,260,620 ± 289,478
Non-specific (Macrophages)
IL-6
2452
1,688↓
2,557
2,407
309 ± 1,241
289 ± 355
TNF-α
43
27↓
98
120
37 ± 83
41 ± 142
Chemokines
MCP-1
10
2↓
44
43
63 ± 19
66 ± 26
MIP-1α
224
130↓
357
237
2 ± 0.2
2.5 ± 2.5
tblfn
Serum, splenocytes, and salivary gland DLNs were collected at the end of the study. Splenocytes and DLN cells were pooled according to vector treatment group. Culture supernatants were collected following incubation with or without ConA for 48 h. Cultures and serum were then analyzed for levels of the indicated cytokines (in pg/ml) by multi-cytokine assay in duplicate. For cell cultures, values are the mean of duplicate tests of ConA treated cells subtracted from media alone. For serum, the data shown were the median ± SD of each group of mice (AAV2-LacZ [n = 6] and AAV2-CTLA4IgG [n = 7], respectively]. Mann-Whitney U test was used to analyze differences of cytokine production in serum. ↑: Production of cytokines in the AAV2-CTLA4IgG group is ≥ 50% higher than in AAV2-LacZ group; ↓: Production of cytokines in the AAV2-CTLA4IgG group is ≥ 50% lower than the AAV2-LacZ group.
Effect of CTLA4IgG on regulation of systemic T cell response in the C57BL/6.NOD-Aec1Aec2 mice
To test for changes in the systemic immune system, cytokines were also measured in serum and in spleen cell cultures. Wide variation was seen in cytokine values in serum, and none of the cytokine levels from the CTLA4IgG and LacZ groups showed statistical significance. However, a decrease (a change in the median of ≥ 50%) in a majority of cytokines associated with Th1 and Th17 cells, such as IFN-γ, IL-18, IL-17, and IL-23, was seen in the serum of AAV2-CTLA4IgG-treated mice compared with AAV2-LacZ-treated mice. In addition, production of IL-12, IL-18, IL-17, and IL-23 from splenocytes was down-regulated in the AAV2-CTLA4IgG-treated group compared with the AAV2-LacZ-treated mice. Unlike the local immune response seen in the SG associated DLN, minimal change in non-specific cytokines, chemokines, or TGF-β1 was detected in serum or cultured splenocytes. These data imply that CTLA4IgG expression can also decrease proinflammatory cytokines in the peripheral immune system, following local SG gene transfer in C57BL/6.NOD-Aec1Aec2 mice (Table 1).
Discussion
The blockade of CD28 co-stimulation by recombinant CTLA4IgG (abatacept) has demonstrated clinical utility in the treatment of rheumatoid arthritis 14. In our study, local expression of CTLA4IgG by gene transfer to the SGs of C57BL/6.NOD-Aec1Aec2 mice, a pSS animal model, resulted in a decrease in the sialoadenitis and improvement in gland function compared with mice that received a control vector.
The advantage of localized gene transfer is to direct the expression of the therapeutic molecule to the site of maximum effect while minimizing the systemic complications that can be associated with off target effects. Using this approach we were able to achieve much higher local concentrations of CTLA4IgG in the salivary glands compared to circulating levels in the serum. Our data further confirm that ductal cells within the gland represent a good depot site for production of recombinant proteins B32 32. Indeed, previous experiments have demonstrated expression from salivary gland ductal cells for the life of the animal B33 33.
In both patients and C57BL/6.NOD-Aec1Aec2 mice, activated CD4+ T lymphocytes including Th1 and Th17 cells infiltrate the salivary and lachrymal glands, and produce a variety of proinflammatory cytokines, such as IFN-γ and IL-17, which may trigger gland damage and represent a crucial element in the pathogenesis of pSS 2B34 34. Although not statistically significant, we did detect a decrease in Th17 cytokine in both the DLN and spleen following expression of CTLA4IgG, suggesting a corrective shift in this critical cell population.
Besides the negative effect on T cells as a result of blockade of the B7:CD28 costimulatory pathway 19, it is also noted that recombinant CTLA4IgG may directly or indirectly deactivate DCs, macrophages and B lymphocytes 1521. Our data indicate that in C57BL/6.NOD-Aec1Aec2 mice, CTLA4IgG expression results in a decrease in T and B lymphocytes as well as DCs and macrophages in the SG that is accompanied by a down-regulation in proinflammatory cytokines. Our finding is in agreement with previous reports on the effect of CTLA4IgG in other autoimmue disease model 2021.
Interestingly, a significant increase in TGF-β1 expression in both the SG and the DLNs was observed. The increase in TGF-β1 expression maybe related to an increase in nTreg or negative regulation of epithelial cells by CTLA4IgG 15. In addition to its role in the immune system, TGF-β1 expression was found to be important in maintaining epithelial tight junctions, an important component in the fluid movement of SGs B35 35 and therefore may be directly related to the improvement in saliva flow.
Our study suggests an improvement of SG function, which could result from the inhibition of sialadenitis after local expression of CTLA4IgG. This suggests that local delivery of AAV2-CTLA4IgG is a promising treatment of pSS. In addition, some improvement in lachrymal gland was also observed. This difference is likely related to the lower circulating levels of CTLA4IgG in the serum compared with the levels in the salivary gland. Despite the positive results achieved in this study, the circulating levels of CTLA4IgG are well below those clinically used with abatacept (http://packageinserts.bms.com/pi/pi_orencia.pdf). Further increases in the dose of vector or the use of vectors with improved gene transfer activity in the salivary gland are likely to result in higher circulating levels and may have a more significant impact on extraglandular manifestations of Sjögren's syndrome.
Gene therapy is still considered an experimental procedure. However, to date more than 200 clinical trials have been conducted and recently many are showing promising results in treating hemophilia, cancer, immunodeficiencies, and blindness. An ongoing trial targeting the salivary glands is also reporting positive results suggesting that gene transfer to the salivary gland is possible B36 36. In summary, our data suggest that inhibition of the costimulatory pathway CD28 by expression of CTLA4IgG locally in the salivary gland can be a useful approach for reducing the inflammation and improving the secretory activity associated with Sjögren's syndrome.
Conclusions
Our data suggest expression of CTLA4IgG can reduce the sialadenitis and improve secretory activity in a mouse model of pSS. In addition to identifying a novel intervention in pSS, our findings support the importance of co-stimulatory pathways as a therapeutic target of the disease.
Abbreviations
AAV2: adeno-associated virus vector serotype 2; ANA: antinuclear antibodies; APC: antigen-presenting cell; CMV: cytomegalovirus; CTLA-4: Cytotoxic T-lymphocyte antigen 4; CTLA4-IgG: CTLA4-immunoglublin; DMEM: Dulbecco's modified Eagle's medium; IFN-γ: Interferon-γ; IL: interleukin; IM: intramuscular injection; ITRs: inverted terminal repeat; LF: lymphocyte foci; LG: lachrymal glands; MAP: multiple antigenic peptide; MCP-1: mast cell proteinase-1; MIP-1: macrophage inflammatory proteins-1; pSS: primary Sjögren's syndrome; SG: salivary gland; TGF-β1: transforming growth factor-β1; TNF-α: tumor necrosis factor-alpha; Treg: T regulatory cells.
Competing interests
This work was supported by an NIH NIDCR intramural research grant to JAC. None of the authors have a financial disclosure.
Authors' contributions
All authors were involved in drafting the article, revising it, and made important intellectual contributions. All authors approved the final version. Dr Chiorini had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. HY, CQN, ABP, and JAC were responsible for the study concept and design. HY, CQN, and YS were responsible for data acquisition. HY, CQN, YS, and JAC were responsible for the analysis and interpretation of the data.
bm
ack
Acknowledgements
The authors thank Dr Gabor G Illei for critical review and helpful discussion of this manuscript.
refgrp Chloroquine-resistant Plasmodium falciparum: now in Pakistani PunjabFoxEKhaliqAASarwarMStricklandGTLancet198511432lpage 14352861372Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndromeVoulgarelisMTzioufasAGNat Rev Rheumatol2010652953710.1038/nrrheum.2010.118link fulltext 20683439CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogren's syndromeXanthouGTapinosNIPolihronisMNezisIPMargaritisLHMoutsopoulosHMClin Exp Immunol199911815416310.1046/j.1365-2249.1999.01037.xpmcid 190540210540173T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjogren's syndromeSkopouliFNFoxPCGalanopoulouVAtkinsonJCJaffeESMoutsopoulosHMJ Rheumatol1991182102141827160Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionGenoveseMCBeckerJCSchiffMLuggenMSherrerYKremerJBirbaraCBoxJNatarajanKNuamahILiTArandaRHagertyDTDougadosMN Engl J Med20053531114112310.1056/NEJMoa05052416162882Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrateBombardieriMBaroneFPittoniVAlessandriCConigliaroPBladesMCPrioriRMcInnesIBValesiniGPitzalisCArthritis Res Ther20046R44745610.1186/ar120954628015380044Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjogren's syndromeVostersJLLandek-SalgadoMAYinHSwaimWDKimuraHTakPPCaturegliPChioriniJAArthritis Rheum2009603633364110.1002/art.24980284913119950301Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and miceNguyenCQHuMHLiYStewartCPeckABArthritis Rheum20085873474310.1002/art.23214285005918311793Interferon-gamma induces persistent depletion of internal Ca2+ stores in a human salivary gland cell lineWuAJChenZJBaumBJAmbudkarISAm J Physiol1996270C5145218779914Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transferNguyenCQYinHLeeBHCarcamoWCChioriniJAPeckABArthritis Res Ther201012R22010.1186/ar3207304653321182786The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune diseaseLeungSLiuXFangLChenXGuoTZhangJCell Mol Immunol2010718218910.1038/cmi.2010.2220383174T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren's syndromeLiXLiXQianLWangGZhangHWangXChenKZhaiZLiQWangYHarrisDCJ Rheum2007342438244518050367Autoimmune Sjogren's-like lesions in salivary glands of TGF-beta1-deficient mice are inhibited by adhesion-blocking peptidesMcCartney-FrancisNLMizelDERedmanRSFrazier-JessenMPanekRBKulkarniABWardJMMcCarthyJBWahlSMJ Immunol1996157130613128757639Regulation of CTLA-4 expression during T cell activationPerkinsDWangZDonovanCHeHMarkDGuanGWangYWalunasTBluestoneJListmanJFinnPWJ Immunol1996156415441598666782Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4TakahashiTTagamiTYamazakiSUedeTShimizuJSakaguchiNMakTWSakaguchiSJ Exp Med200019230331010.1084/jem.192.2.303219324810899917Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune diseaseSakaguchiSOnoMSetoguchiRYagiHHoriSFehervariZShimizuJTakahashiTNomuraTImmunol Rev200621282710.1111/j.0105-2896.2006.00427.x16903903Glandular and extraglandular expression of costimulatory molecules in patients with Sjogren's syndromeMatsumuraRUmemiyaKGotoTNakazawaTKagamiMTomiokaHTanabeESugiyamaTSueishiMAnn Rheum Dis20016047348210.1136/ard.60.5.473175363111302869Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndromeDownie-DoyleSBayatNRischmuellerMLesterSArthritis Rheum2006542434244010.1002/art.2200416869018AbataceptMorelandLBateGKirkpatrickPNat Rev Drug Discov2006518518610.1038/nrd198916557658Cre/loxP-mediated CTLA4IgG gene transfer induces clinically relevant immunosuppression via on-off gene recombination in vivoIzawaASanoKTakeharaMInobeMSuzukiJImamuraHTakahashiMIkedaUIsobeMUedeTCardiovasc Res20066928929710.1016/j.cardiores.2005.07.02116185671CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine productionCutoloMSoldanoSMontagnaPSulliASerioloBVillaggioBTrioloPClericoPFelliLBrizzolaraRArthritis Res Ther200911R17610.1186/ar2865300352019930661Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndromeKokMRYamanoSLoddeBMWangJCouwenhovenRIYakarSVoutetakisALeroithDSchmidtMAfioneSPillemerSRTsutsuiMTTakPPChioriniJABaumBJHum Gene Ther2003141605161810.1089/10430340332254225714633403Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificityKaludovNBrownKEWaltersRWZabnerJChioriniJAJ Virol2001756884689310.1128/JVI.75.15.6884-6893.200111441611435568Combined gene therapy with adenovirus vectors containing CTLA4Ig and CD40Ig prolongs survival of composite tissue allografts in rat modelKanayaKTsuchidaYInobeMMurakamiMHiroseTKonSKawaguchiSWadaTYamashitaTIshiiSUedeTTransplantation20037527528110.1097/01.TP.0000046966.35399.7512589145Novel tools for production and purification of recombinant adenoassociated virus vectorsGrimmDKernARittnerKKleinschmidtJAHum Gene Ther19981827452760Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine backgroundChaSNagashimaHBrownVBPeckABHumphreys-BeherMGArthritis Rheum2002461390139810.1002/art.1025812115247Enhanced transduction of mouse salivary glands with AAV5-based vectorsKatanoHKokMRCotrimAPYamanoSSchmidtMAfioneSBaumBJChioriniJAGene Ther20061359460110.1038/sj.gt.330269116341060Inhibition of experimental autoimmune uveitis by amino acid copolymersYinHVisticaBPChanCCStromingerJLGeryIJ Neuroimmunol2009215434810.1016/j.jneuroim.2009.08.002292805619748134Differential gene expression in the salivary gland during development and onset of xerostomia in Sjogren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouseNguyenCQSharmaALeeBHSheJXMcIndoeRAPeckABArthritis Res Ther200911R5610.1186/ar2676268820719379516Serological diagnosis of primary Sjogren's syndrome by means of human recombinant La (SS-B) as nuclear antigenWhittinghamSNaselliGMcNeilageLJCoppelRLSturgessADLancet19872132885503The histopathology of Sjogren's syndrome in labial salivary gland biopsiesGreenspanJSDanielsTETalalNSylvesterRAOral Surg Oral Med Oral Pathol19743721722910.1016/0030-4220(74)90417-44589360Gene therapy: some history, applications, problems, and prospectsCotrimAPBaumBJToxicol Pathol2008369710310.1177/019262330730992518337227Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeuticsVoutetakisAKokMRZhengCBossisIWangJCotrimAPMarracinoNGoldsmithCMChioriniJALohYPNiemanLKBaumBJProc Natl Acad Sci USA20041013053305810.1073/pnas.040013610136574314978265Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndromeTsunawakiSNakamuraSOhyamaYSasakiMIkebe-HirokiAHirakiAKadenaTKawamuraEKumamaruWShinoharaMShirasunaKJ Rheumatol2002291884189612233883Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeabilityHoweKLReardonCWangANazliAMcKayDMAm J Pathol20051671587159710.1016/S0002-9440(10)61243-6161320216314472Gene delivery in salivary glands: from the bench to the clinicSamuniYBaumBJBiochim Biophys Acta201118121515152121763423